


pharmaceuticals

IMPACT
FACTOR
5.863



CPPs to the Test: Effects on Binding, Uptake and Biodistribution of a Tumor Targeting Nanobody

Volume 14 • Issue 7 | July 2021



mdpi.com/journal/pharmaceuticals
ISSN 1424-6247

Editorial Board



- **Editorial Board**
- **Medicinal Chemistry Section**
(/journal/pharmaceuticals/sectioneditors/pharm_medicinal_chemistry)
- **Biopharmaceuticals Section** (/journal/pharmaceuticals/sectioneditors/biopharmaceuticals)
- **Natural Products Section** (/journal/pharmaceuticals/sectioneditors/natural_products)
- **Radiopharmaceutical Sciences Section**
(/journal/pharmaceuticals/sectioneditors/radiopharmaceutical_sciences)
- **Pharmacology Section** (/journal/pharmaceuticals/sectioneditors/pharm-pharmacology)
- **Pharmaceutical Technology Section**
(/journal/pharmaceuticals/sectioneditors/pharmaceutical_technology)

Editors (15)



Dr. Jean Jacques Vanden Eynde

Website1 (<http://www.cilbiotech.be/jj/>) **Website2** (<https://publons.com/researcher/1447855/jean-jacques-vanden-eynde>) **SciProfiles** (<https://sciprofiles.com/profile/93338>)

Editor-in-Chief

Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium

Interests: heterocycles; microwave-induced synthesis; medicinal chemistry; green chemistry

Special Issues, Collections and Topics in MDPI journals

Dr. Daniela De Vita

Website (https://phd.uniroma1.it/web/DE-VITA-DANIELA_nC2550.aspx)

Section Editor-in-Chief

Department of Environmental Biology, Sapienza University of Rome, Rome, Italy

Interests: medicinal plants; phytochemistry; antifungal agents; antiparasitic agents

Special Issues, Collections and Topics in MDPI journals



Prof. Dr. Gary J. Stephens

Website (<https://www.reading.ac.uk/pharmacy/about/staff/g-j-stephens.aspx>)

SciProfiles (<https://sciprofiles.com/profile/43946>)

Section Editor-in-Chief

School of Pharmacy, University of Reading, Whiteknights, PO Box 228, Reading RG6 6AJ, UK

Interests: electrophysiology; voltage-gated calcium channels; cannabinoids; ion channels; GPCRs; pain; ataxia

Special Issues, Collections and Topics in MDPI journals



Dr. Alfredo Berzal-Herranz

Website ([http://www.ipb.csic.es/departamentos/aberzalh_ingles.html?](http://www.ipb.csic.es/departamentos/aberzalh_ingles.html?depto=MolecularBiologyDepartment)

depto=MolecularBiologyDepartment) **SciProfiles** (<https://sciprofiles.com/profile/19235>)

Section Editor-in-Chief

Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra, (IPBLN-CSIC), PTS Granada, Av del Conocimiento 17, 18016 Granada, Spain

Interests: structure-function of RNA; aptamers; antisense; ribozymes; viral RNA genomes; RNA as tool; therapeutic RNAs

Special Issues, Collections and Topics in MDPI journals



Prof. Dr. Gill Diamond

Website (<https://louisville.edu/dentistry/departments/oralhealth/faculty/gill-diamond-phd>)

SciProfiles (<https://sciprofiles.com/profile/66473>)

Section Editor-in-Chief

Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, Louisville, KY 40292, USA

Interests: regulation of innate immunity; antimicrobial peptides; antifungal peptides; defensins; cathelicidins; novel antiviral compounds

Special Issues, Collections and Topics in MDPI journals



Prof. Dr. Mary J. Meegan

Website (<http://www.pharmacy.tcd.ie/staff/meegan-cv.php>)

SciProfiles (<https://sciprofiles.com/profile/162157>)

Section Editor-in-Chief

School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152–160 Pearse Street, Dublin 2 D02 R590, Ireland

Interests: anticancer drug design; breast cancer; novel antiestrogens; tubulin targeting agents;

azetidiones, antiestrogen-drug conjugates; estrogen receptor; Burkitt's Lymphoma; Chronic Lymphocytic Leukaemia

Special Issues, Collections and Topics in MDPI journals



Prof. Dr. Serge Mordon

Website1 (<http://www.biotis-bordeaux.com/>) **Website2** (<http://www.oncothai.fr/>)

SciProfiles (<https://sciprofiles.com/profile/583847>)

Section Editor-in-Chief

INSERM (French National Institute of Health and Medical Research) U1026, The Laboratory of the Bioengineering of Tissues (BioTis), University of Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux, France

Interests: photodynamic therapy; cancer; clinical evaluation; photosensitizer; dosimetry; Fluorescencer; Dosimetry; Fluorescence

Special Issues, Collections and Topics in MDPI journals



Prof. Dr. Amélia Pilar Rauter

Website (<https://webpages.ciencias.ulisboa.pt/~aprauter/>)

Section Editor-in-Chief

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Interests: carbohydrate small molecule synthesis; organic and biomolecular chemistry developments towards new therapeutic approaches for diabetes; Alzheimer's disease and other amyloid diseases and carbohydrate-based antibiotics

Special Issues, Collections and Topics in MDPI journals



Dr. Irina Velikyan

Website (<https://katalog.uu.se/profile/?id=N1-184>)

SciProfiles (<https://sciprofiles.com/profile/113591>)

Section Editor-in-Chief

Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden

Interests: nuclear medicine; positron emission tomography; molecular imaging; radiopharmaceutical sciences; cancer; diabetes; fibrosis; drug development



Prof. Dr. Thomas Efferth

Website (<https://www.cinema.uni-mainz.de/prof-dr-thomas-efferth/>)

SciProfiles (<https://sciprofiles.com/profile/9530>)

Associate Editor

Department of Pharmaceutical Biology, Institute of Pharmacy and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany

Interests: Natural products; Transcriptomics; Network pharmacology; Personalized medicine; Virtual drug screening

Special Issues, Collections and Topics in MDPI journals



Prof. Dr. Joachim Jose

Website (<https://www.uni-muenster.de/Chemie.pz/forschen/ag/jose/index.html>)

SciProfiles (<https://sciprofiles.com/profile/123628>)

Associate Editor

PharmaCampus Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität, Corrensstr. 48, 48149 Muenster, Germany

Interests: autodisplay; assay development and inhibitor testing; whole cell biocatalysts for synthesis of drugs and building blocks; directed evolution of enzyme inhibitors and biocatalysts; biosensor development and diagnostic tools

Special Issues, Collections and Topics in MDPI journals



Dr. Klaus Kopka

Website (<https://www.hzdr.de/db/Cms?pNid=130>)

SciProfiles (<https://sciprofiles.com/profile/907163>)

Associate Editor

Helmholtz-Zentrum Dresden-Rossendorf (HZDR) e.V., Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany

Interests: radiopharmaceutical sciences; labeling chemistry; medicinal chemistry; PET tracers; radiopharmaceuticals for diagnostics and endoradiotherapy; small molecules; peptides; antibodies and derivatives thereof

Special Issues, Collections and Topics in MDPI journals



Dr. Annie Mayence

Website (<https://orcid.org/0000-0003-2509-7593>)

SciProfiles (<https://sciprofiles.com/profile/468756>)

Associate Editor



Formerly professor at the Haute Ecole Provinciale de Hainaut-Condorcet, 7330 Saint-Ghislain, Belgium

Interests: medicinal chemistry; organic synthesis; parasitic diseases; orphan drugs

Special Issues, Collections and Topics in MDPI journals



Prof. Dr. Maria Emília de Sousa

Website (<http://www.ff.up.pt/esousa>) **SciProfiles** (<https://sciprofiles.com/profile/148085>)

Associate Editor

1. Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências, Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal

2. Interdisciplinar de Investigação Marinha e Ambiental (CIIMAR/CIMAR), Universidade do Porto, Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos, S/N 4450-208 Matosinhos, Portugal

Interests: medicinal chemistry; organic synthesis; heterocycles, P-glycoprotein; anticancer; anticoagulants; chiral drugs; marine natural products

Special Issues, Collections and Topics in MDPI journals

Dr. Guangshun Wang

Website (<https://www.unmc.edu/pathology/faculty/bios/wang.html>)

SciProfiles (<https://sciprofiles.com/profile/47472>)

Associate Editor

Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-5900, USA

Interests: host defense antimicrobial peptides; structural bioinformatics; biomolecular NMR

Special Issues, Collections and Topics in MDPI journals

Editorial Board Members (101)

Filter Editorial Board Members

Filter



Prof. Dr. Paolo Arosio



Website (https://www.researchgate.net/profile/Paolo_Arosio)

Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy

Interests: iron metabolism; ferritin; iron storage

Special Issues, Collections and Topics in MDPI journals

Special Issue in ***Pharmaceuticals: Iron as Therapeutic Targets in Human Diseases***
(/journal/pharmaceuticals/special_issues/Iron_TTHD)

Special Issue in ***International Journal of Molecular Sciences: New Advances in Iron Metabolism, Ferritin and Hepcidin Research*** (/journal/ijms/special_issues/iron_metabolism2)



Prof. Dr. Atanas G. Atanasov

Website (<https://inpst.net/contact/>) **SciProfiles** (<https://sciprofiles.com/profile/145530>)

1. Ludwig Boltzmann Institute for Digital Health and Patient Safety, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria

2. Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Jastrzebiec, 05-552 Magdalenka, Poland

Interests: molecular medicine; biotechnology; digital health; open innovation; natural products

Special Issues, Collections and Topics in MDPI journals

Special Issue in ***Molecules: Effects of Natural Products in the Context of Cardiometabolic Disease***
(/journal/molecules/special_issues/cardiometabolic_disease)

Special Issue in ***Molecules: Selected Papers from the 8th Central European Conference 'Chemistry towards Biology' (CTB-2016)*** (/journal/molecules/special_issues/CTB_2016)

Special Issue in ***Molecules: Selected Papers from the 46th EuroCongress on Drug Synthesis and Analysis (ECDSA-2017)*** (/journal/molecules/special_issues/ECDSA2017)

Special Issue in ***Molecules: Bioactive Molecules and Their Mechanisms of Action***
(/journal/molecules/special_issues/molecules_mec)



Prof. Dr. Rachel Auzély

Website (<https://biopolymers.insightconferences.com/speaker/2016/rachel-auzely-velty-university-grenoble-alpes-france>)

Centre de Recherches sur les Macromolécules Végétales (CERMAV)-CNRS, University Grenoble Alpes, 38400 Saint Martin d'Herès, France

Interests: biomaterial design; polysaccharide hydrogels; drug delivery nanosystems; stem cell therapy, cancer therapy, 3D bioprinting

Special Issues, Collections and Topics in MDPI journals



Prof. Dr. Jean-Pierre Bazureau

Website (<https://iscr.univ-rennes1.fr/jean-pierre-bazureau>)

SciProfiles (<https://sciprofiles.com/profile/14544>)

Institut des Sciences Chimiques de Rennes (ISCR), UMR CNRS 6226, Groupe CORINT, Université de Rennes 1 (UR1), Campus de Beaulieu, Bât. 10A, 263 Avenue du Général Leclerc, CS 74205, 35042 Rennes CEDEX, France

Interests: microwave-assisted organic chemistry and scale-up; “Store Operated Calcium Entry” inhibitors (Orai1) for cancer via Délikine program inhibitors; mitochondrial ion channel inhibitors for cancer; protein kinase (PKs) inhibitors for CNS (Alzheimer’s disease and Down syndrome) via Leucettine program inhibitors; fluorescence probes for studies of molecular mechanisms in cancer biology

Special Issues, Collections and Topics in MDPI journals

Special Issue in *Pharmaceuticals: Heterocyclic Chemistry for Cancer and CNS Diseases*

(/journal/pharmaceuticals/special_issues/HeteroC_CCNS)

Special Issue in *Pharmaceuticals: Biomedical Applications of Fluorescent Gold Nanotechnologies*

(/journal/pharmaceuticals/special_issues/Fluorescent_Gold_Nanotech)

Special Issue in *Molecules: Microwave Irradiation in Organic Chemistry*

(/journal/molecules/special_issues/microwave_organic)



Dr. Martina Benešová

Website (https://www.researchgate.net/profile/Martina_Benesova2)

SciProfiles (<https://sciprofiles.com/profile/720157>)

Research Group Molecular Biology of Systemic Radiotherapy, Research Program Imaging and Radiooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 223, D-69120 Heidelberg, Germany

Interests: radiopharmaceutical chemistry; coordination chemistry; theranostic radiopharmaceuticals; molecular biology of systemic therapy; radiobiology

Special Issues, Collections and Topics in MDPI journals

Special Issue in *Pharmaceuticals: The Future Direction of Radiopharmaceutical Development for Cancer Theranostics* (/journal/pharmaceuticals/special_issues/radiopharmaceutical_cancer)

Special Issue in *Pharmaceuticals: Targeted Radionuclide Therapy (TRNT) in Modern Cancer Management* (/journal/pharmaceuticals/special_issues/Radionuclide_Cancer)



Prof. Dr. Simona Bertoni

[Website \(https://www.unipr.it/ugov/person/19178\)](https://www.unipr.it/ugov/person/19178)

[SciProfiles \(https://sciprofiles.com/profile/769272\)](https://sciprofiles.com/profile/769272)

Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy

Interests: Pharmacology; intestinal inflammation; Eph-ephrin system; Eph-ephrin ligands; cholinergic receptors; mesenteric ischemia-reperfusion; serotonin and histamine ligands

Special Issues, Collections and Topics in MDPI journals

Special Issue in **[Pharmaceuticals: Targeting the Eph-ephrin System](/journal/pharmaceuticals/special_issues/Eph_ephrin)**
(/journal/pharmaceuticals/special_issues/Eph_ephrin)



Prof. Dr. Thierry Besson

[Website \(https://www.researchgate.net/profile/Thierry-Besson\)](https://www.researchgate.net/profile/Thierry-Besson)

[SciProfiles \(https://sciprofiles.com/profile/84052\)](https://sciprofiles.com/profile/84052)

Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, F-76000 Rouen, France

Interests: chemistry of heterocyclic compounds; microwave-assisted chemistry; sustainable methodologies; green chemistry applied to bioactive compounds: kinase inhibitors; Alzheimer's disease; Down syndrome; cancer

Special Issues, Collections and Topics in MDPI journals

Special Issue in **[Molecules: Focusing on Sulfur in Medicinal Chemistry](/journal/molecules/special_issues/Sulfur)**
(/journal/molecules/special_issues/Sulfur)

Special Issue in **[Scientia Pharmaceutica: Kinase Inhibitors in Cancer and Central Nervous System](/journal/scipharm/special_issues/kinaseinhibitors_cancer_CNS)**
(/journal/scipharm/special_issues/kinaseinhibitors_cancer_CNS)

Special Issue in **[Pharmaceuticals: Recent Contributions in Medicinal Chemistry Within European GP2A Network](/journal/pharmaceuticals/special_issues/GP2A)**
(/journal/pharmaceuticals/special_issues/GP2A)

Special Issue in **[Pharmaceuticals: Heterocyclic Compounds and Their Application in Therapy](/journal/pharmaceuticals/special_issues/heterocyclic_compounds_therapy)**
(/journal/pharmaceuticals/special_issues/heterocyclic_compounds_therapy)

Special Issue in **[Pharmaceuticals: Perspectives and Challenges in Heterocyclic Chemistry- XXIX European Colloquium on Heterocyclic Chemistry \(ECHC 2021\)](/journal/pharmaceuticals/special_issues/ECHC_2021)**
(/journal/pharmaceuticals/special_issues/ECHC_2021)

Special Issue in **[Molecules: Microwave Irradiation in Organic Chemistry](/journal/molecules/special_issues/microwave_organic)**
(/journal/molecules/special_issues/microwave_organic)



Prof. Dr. Giuseppe Biagini

[Website \(http://personale.unimore.it/rubrica/dettaglio/gbiagini\)](http://personale.unimore.it/rubrica/dettaglio/gbiagini)

[SciProfiles \(https://sciprofiles.com/profile/258520\)](https://sciprofiles.com/profile/258520)

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia,
41100 Modena, Italy

Interests: animal ethics; animal welfare; epilepsy models; neuroprotection; stress management

Special Issues, Collections and Topics in MDPI journals



Special Issue in *International Journal of Molecular Sciences: Epilepsy: From Molecular Mechanisms to Targeted Therapies* (/journal/ijms/special_issues/epilepsy_2019)

Special Issue in *International Journal of Molecular Sciences: Epilepsy: From Molecular Mechanisms to Targeted Therapies 2.0* (/journal/ijms/special_issues/epilepsy_2020)

Special Issue in *International Journal of Molecular Sciences: Epilepsy: From Molecular Mechanisms to Targeted Therapies 3.0* (/journal/ijms/special_issues/epilepsy2021)



Prof. Dr. Célia Cabral

Website (<https://www.cienciavitae.pt/portal/en/D913-F7DD-2713>)

SciProfiles (<https://sciprofiles.com/profile/797210>)

Coimbra Institute for Clinical and Biomedical Research (iCBR)/Center for Innovative Biomedicine and Biotechnology (CIBB)/Clinical Academic Center of Coimbra (CACC), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal

Interests: ethnomedicine; phytochemistry; natural products; bioactive compounds; plant-based health solutions

Special Issues, Collections and Topics in MDPI journals

Special Issue in *Agronomy: Analysis of Bioactive Compounds from Medicinal Plants and Promising Applications* (/journal/agronomy/special_issues/Plants_Compounds)



Dr. Conor R. Caffrey

Website (<https://pharmacy.ucsd.edu/faculty/bios/caffrey.shtml>)

Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA

Interests: small molecule drug discovery for parasitic protozoa and helminths; 'neglected' tropical diseases; high-throughput and high content screening; proteolysis

Pharmaceuticals (</journal/pharmaceuticals>), EISSN 1424-8247, Published by MDPI **Disclaimer**

RSS (</rss/journal/pharmaceuticals>) **Content Alert** (</journal/pharmaceuticals/toc-alert>)

Further Information

Article Processing Charges (</apc>)

Pay an Invoice (</about/payment>)

Open Access Policy (</openaccess>)

- [Vol. 14 \(2021\) \(/1424-8247/14\)](#)
- [Vol. 13 \(2020\) \(/1424-8247/13\)](#)
- [Vol. 12 \(2019\) \(/1424-8247/12\)](#)
- [Vol. 11 \(2018\) \(/1424-8247/11\)](#)
- [Vol. 10 \(2017\) \(/1424-8247/10\)](#)
- [Vol. 9 \(2016\) \(/1424-8247/9\)](#)
- [Vol. 8 \(2015\) \(/1424-8247/8\)](#)
- [Vol. 7 \(2014\) \(/1424-8247/7\)](#)
- [Vol. 6 \(2013\) \(/1424-8247/6\)](#)
- [Vol. 5 \(2012\) \(/1424-8247/5\)](#)
- [Vol. 4 \(2011\) \(/1424-8247/4\)](#)
- [Vol. 3 \(2010\) \(/1424-8247/3\)](#)
- [Vol. 2 \(2009\) \(/1424-8247/2\)](#)
- [Vol. 1 \(2004\) \(/1424-8247/1\)](#)



Affiliated Society:



(https://serve.mdpi.com/www/my_files/clilik.php?oaparams=0&bannerid=7061&zoneid=4&cb=3697464507oad)

Pharmaceuticals, Volume 14, Issue 7 (July 2021) – 105 articles



Cover Story ([view full-size image \(/files/uploaded/covers/pharmaceuticals/big_cover-pharmaceuticals-v14-i7.png\)](#)): Cell-Penetrating Peptides (CPPs) and nanobodies could combine into powerful targeting tools, if we optimize their synergy. Nanobodies are low molecular weight antigen-specific binders that show good tissue penetration. However, their fast clearance narrows the time window in which nanobodies distribute into the target tissue. CPPs could increase tissue accumulation of nanobodies, by enhancing their cellular uptake. Several CPPs enhance the uptake of the epidermal growth factor receptor-targeting nanobody 7D12 in monolayer cultures and cell spheroids. The physicochemical properties of each CPP influence those of the whole conjugate. Differences between CPPs suggest that future research should focus on understanding which and how physicochemical properties of CPP conjugates drive optimal biodistribution. [View this paper \(https://www.mdpi.com/1424-8247/14/7/602\)](https://www.mdpi.com/1424-8247/14/7/602)

(<https://www.mdpi.com/1424-8247/14/7/602>)

regarded as officially published after their release is announced to the [table of contents alert mailing list \(/journal/pharmaceuticals/toc-alert\)](#).

- You may [sign up for e-mail alerts \(/journal/pharmaceuticals/toc-alert\)](#) to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free [Adobe Reader \(https://www.adobe.com/\)](https://www.adobe.com/) to open them.

Order results

Publication Date

Result details

Normal

Section

All Sections

Show export options

Open Access Review

(/1424-8247/14/7/701/pdf)

Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) ¹⁸F-Radiopharmaceuticals (/1424-8247/14/7/701)

- by [Lexi Gower-Fry \(https://sciprofiles.com/profile/1710380\)](https://sciprofiles.com/profile/1710380), [Travis Kronemann \(https://sciprofiles.com/profile/1728043\)](https://sciprofiles.com/profile/1728043), [Andreas Dorian \(https://sciprofiles.com/profile/author/OUozZW5KbUNtbnJUMVIUd0xpOUVHa2VkS0lpU2VEZGowQlZLcVZwbWswST0=\)](https://sciprofiles.com/profile/author/OUozZW5KbUNtbnJUMVIUd0xpOUVHa2VkS0lpU2VEZGowQlZLcVZwbWswST0=), [Yinglan Pu \(https://sciprofiles.com/profile/author/MGFxNGs4NEkrUIRr3JrWXc2MzI5NURZOFFwbWRBR3IIN082SkRlbjVaYz0=\)](https://sciprofiles.com/profile/author/MGFxNGs4NEkrUIRr3JrWXc2MzI5NURZOFFwbWRBR3IIN082SkRlbjVaYz0=), [Carolin Jaworski \(https://sciprofiles.com/profile/author/djE4ZW9URHN0dkVuS1ZMQ3FIVjAwZ1dDMFNFUUFFidUVHSk81cUNCZHNxQT0=\)](https://sciprofiles.com/profile/author/djE4ZW9URHN0dkVuS1ZMQ3FIVjAwZ1dDMFNFUUFFidUVHSk81cUNCZHNxQT0=), [Carmen Wängler \(https://sciprofiles.com/profile/46194\)](https://sciprofiles.com/profile/46194), [Peter Bartenstein \(https://sciprofiles.com/profile/1591166\)](https://sciprofiles.com/profile/1591166), [Leonie Beyer \(https://sciprofiles.com/profile/1414440\)](https://sciprofiles.com/profile/1414440), [Simon Lindner \(https://sciprofiles.com/profile/1591149\)](https://sciprofiles.com/profile/1591149), [Klaus Jurkschat \(https://sciprofiles.com/profile/16287\)](https://sciprofiles.com/profile/16287), [Björn Wängler \(https://sciprofiles.com/profile/23541\)](https://sciprofiles.com/profile/23541), [Justin J. Bailey \(https://sciprofiles.com/profile/1726319\)](https://sciprofiles.com/profile/1726319) and [Ralf Schirmacher \(https://sciprofiles.com/profile/146560\)](https://sciprofiles.com/profile/146560)

We use cookies on our website to enhance your navigation, analyze site usage, and assist in our marketing efforts. (<https://doi.org/10.3390/ph14070701>) - 20 Jul 2021

Read more about our cookies [here \(/about/privacy\)](#).

Abstract The incorporation of silicon fluoride acceptor (SiFA) moieties into a variety of molecules, such as peptides, proteins and biologically relevant small molecules, has improved the generation of ¹⁸F-radiopharmaceuticals for medical imaging. The efficient isotopic exchange process, in combination with the enhanced [...] [Read more.](#)

Back to Top

► **Show Figures**

- [\(/pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g001-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g001-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g002-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g002-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g003-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g003-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g004-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g004-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g005-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g005-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g006-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g006-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g007-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g007-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g008-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g008-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g009-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g009-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g010-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g010-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g011-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g011-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g012-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00701/article_deploy/html/images/pharmaceuticals-14-00701-g012-550.jpg)

Open Access Review

☰ ⬇️ (/1424-8247/14/7/700/pdf)

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far? (/1424-8247/14/7/700)

by **Theodoros Mavridis** (<https://sciprofiles.com/profile/1083461>),

Christina I. Deligianni (<https://sciprofiles.com/profile/author/N2ZNNUQ3bUkzdFIBd1IVYjFaMThtU3NmMnYzcW5aSXNDL0R3UHV1Z2tvV70=>),

Georgios Karagiorgis (<https://sciprofiles.com/profile/author/aEZwUzJLskVzVjIBYW9ucGJ6aXYxZm82OWJjbExOTUNLVU1KbCs2Rjl6bz0=>),

Ariadne Daponte (<https://sciprofiles.com/profile/author/bIYxUI4Q1piSmpFYzQ4TmPGEI0YUd3TjBITWx1dHpmL2JvZ0JXRg1WMD0=>)

Marianthi Breza (<https://sciprofiles.com/profile/1030432>) and **Dimos D. Mitsikostas** (<https://sciprofiles.com/profile/1148965>)

Pharmaceuticals 2021, 14(7), 700; <https://doi.org/10.3390/ph14070700> (<https://doi.org/10.3390/ph14070700>) - 20 Jul 2021

Cited by 2 (/1424-8247/14/7/700#citedby) | Viewed by 1490

Abstract Now more than ever is the time of monoclonal antibody use in neurology. In headaches, disease-specific and mechanism-based treatments existed only for symptomatic management of migraines (i.e., triptans), while the standard prophylactic anti-migraine treatments consist of non-specific and repurposed drugs that share limited [...] **Read more.**

(This article belongs to the Section **Biopharmaceuticals** ([/journal/pharmaceuticals/sections/biopharmaceuticals](https://journal.pharmaceuticals/sections/biopharmaceuticals)))

► **Show Figures**

- [\(/pharmaceuticals/pharmaceuticals-14-00700/article_deploy/html/images/pharmaceuticals-14-00700-ag-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00700/article_deploy/html/images/pharmaceuticals-14-00700-ag-550.jpg)

Open Access Article

☰ ⬇️ (/1424-8247/14/7/699/pdf)

Development of Machine Learning Models for Accurately Predicting and Ranking the Activity of Lead Molecules to Inhibit PRC2 Dependent Cancer (/1424-8247/14/7/699)

by **Danishuddin** (<https://sciprofiles.com/profile/author/NGwrRmIMTF4QTloa2N0NkdDd2EybmdYLzIGKzAxMXg2ZEZqQFV6c3dBbz0=>),

Vikas Kumar (<https://sciprofiles.com/profile/1239843>), **Shraddha Parate** (<https://sciprofiles.com/profile/1182244>),

Ashutosh Bahuguna (<https://sciprofiles.com/profile/1031061>), **Gihwan Lee** (<https://sciprofiles.com/profile/500887>),

Myeong Ok Kim (<https://sciprofiles.com/profile/594369>) and **Keun Woo Lee** (<https://sciprofiles.com/profile/15896>)

Pharmaceuticals 2021, 14(7), 699; <https://doi.org/10.3390/ph14070699> (<https://doi.org/10.3390/ph14070699>) - 20 Jul 2021

Viewed by 840

Abstract Disruption of epigenetic processes to eradicate tumor cells is among the most promising interventions for cancer control. EZH2 (Enhancer of zeste homolog 2), a catalytic component of polycomb repressive complex 2 (PRC2), methylates lysine 27 of histone H3 to promote transcriptional silencing and [...] **Read more.**

(This article belongs to the Section **Medicinal Chemistry** ([/journal/pharmaceuticals/sections/pharm_medicinal_chemistry](https://journal.pharmaceuticals/sections/pharm_medicinal_chemistry)))


► **Show Figures**

- [\(/pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g001-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g001-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g002-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g002-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g003-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g003-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g004-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g004-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g005-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g005-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g006-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g006-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g007-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g007-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g008-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g008-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g009-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g009-550.jpg)
- [\(/pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g010-550.jpg\)](https://pharmaceuticals/pharmaceuticals-14-00699/article_deploy/html/images/pharmaceuticals-14-00699-g010-550.jpg)

Accept (/accept_cookies)

Back to TopTop




Functional Characterization of the Oxantel-Sensitive Acetylcholine Receptor from *Trichuris muris* (/1424-8247/14/7/698)

by  Tina V. A. Hansen (<https://sciprofiles.com/profile/1460296>),  Richard K. Grecnis (<https://sciprofiles.com/profile/1308091>),  Mohamed Issouf (<https://sciprofiles.com/profile/author/N3VxQkIDeVYdXBHZZWtuY1VxYnBCTTBmU3J0cGxIalq4UmxaWDBLRS84WT0=>),  Cédric Neveu (<https://sciprofiles.com/profile/1601607>) and  Claude L. Charvet (<https://sciprofiles.com/profile/1070604>)
Pharmaceuticals 2021, 14(7), 698; <https://doi.org/10.3390/ph14070698> (<https://doi.org/10.3390/ph14070698>) - 20 Jul 2021

Viewed by 1052

Abstract The human whipworm, *Trichuris trichiura*, is estimated to infect 289.6 million people globally. Control of human trichuriasis is a particular challenge, as most anthelmintics have a limited single-dose efficacy, with the striking exception of the narrow-spectrum anthelmintic, oxantel. We recently identified a [...] [Read more.](#)

(This article belongs to the Special Issue **Antiparasitics** (/journal/pharmaceuticals/special_issues/antiparasitics))**Show Figures**[\(/pharmaceuticals/pharmaceuticals-14-00698/article_deploy/html/images/pharmaceuticals-14-00698-ag-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00698/article_deploy/html/images/pharmaceuticals-14-00698-ag-550.jpg)[\(/pharmaceuticals/pharmaceuticals-14-00698/article_deploy/html/images/pharmaceuticals-14-00698-g001-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00698/article_deploy/html/images/pharmaceuticals-14-00698-g001-550.jpg)[\(/pharmaceuticals/pharmaceuticals-14-00698/article_deploy/html/images/pharmaceuticals-14-00698-g002-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00698/article_deploy/html/images/pharmaceuticals-14-00698-g002-550.jpg)[\(/pharmaceuticals/pharmaceuticals-14-00698/article_deploy/html/images/pharmaceuticals-14-00698-g003-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00698/article_deploy/html/images/pharmaceuticals-14-00698-g003-550.jpg)**Albumin Nanoparticle Formulation for Heart-Targeted Drug Delivery: In Vivo Assessment of Congestive Heart Failure** (/1424-8247/14/7/697)







by  Nikita Lomis (<https://sciprofiles.com/profile/168060>),  Ziyab K. Sarfaraz (<https://sciprofiles.com/profile/author/enpVVGp6WjhtL05KskFENEZRMId5cXRySFJQNmFBdU1mU1UyYnVUeko4ST0=>),  Aiman Alruwaih (<https://sciprofiles.com/profile/author/SXJyRFI2UkRJSVc3VlhqcXJINfHrVzIKWDA4aU11anBCSkd5aVM1SGhuST0=>),  Susan Westfall (<https://sciprofiles.com/profile/author/YWN3eGtwYnFISXpCQkhuMVJOOFFFNk1NTi9nSEcwa0FFRGIJMXNwK1g5cz0=>),  Dominique Shum-Tim (<https://sciprofiles.com/profile/author/NjQ0NEhtZHRzQ2pVMIFISVnRMTF6V1ZWNURQOVryYXJyWUJDWDFal...z0=>)
 and

 Satya Prakash (<https://sciprofiles.com/profile/18857>)*Pharmaceuticals* 2021, 14(7), 697; <https://doi.org/10.3390/ph14070697> (<https://doi.org/10.3390/ph14070697>) - 19 Jul 2021

Cited by 2 (/1424-8247/14/7/697#citedby) | Viewed by 911

Abstract Congestive heart failure is a fatal cardiovascular disease resulting in tissue necrosis and loss of cardiac contractile function. Inotropic drugs such as milrinone are commonly used to improve the myocardial contractility and heart function. However, milrinone is associated with severe side effects and [...] [Read more.](#)

(This article belongs to the Special Issue **Protein-Based Biomaterial for Pharmaceutical and Biomedical Applications** (/journal/pharmaceuticals/special_issues/Protein-Based_Biomaterial_Pharm_Biomed_application))**Show Figures**[\(/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g001-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g001-550.jpg)[\(/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g002-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g002-550.jpg)[\(/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g003-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g003-550.jpg)[\(/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g004-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g004-550.jpg)[\(/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g005-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g005-550.jpg)[\(/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g006-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g006-550.jpg)[\(/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g007-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g007-550.jpg)[\(/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g008-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g008-550.jpg)[\(/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g009-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g009-550.jpg)[\(/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g010-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g010-550.jpg)[\(/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g011-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00697/article_deploy/html/images/pharmaceuticals-14-00697-g011-550.jpg)**Development and Characterization of *n*-Propyl Gallate Encapsulated Solid Lipid Nanoparticles-Loaded Hydrogel for Intranasal Delivery** (/1424-8247/14/7/696)

by  Fakhara Sabir (<https://sciprofiles.com/profile/1325889>),  Gábor Katona (<https://sciprofiles.com/profile/916549>),  Ruba Ismail (<https://sciprofiles.com/profile/607539>),  Bence Sipos (<https://sciprofiles.com/profile/1179791>),  Rita Ambrus (<https://sciprofiles.com/profile/161462>) and  Ildikó Csóka (<https://sciprofiles.com/profile/1467109>)

Pharmaceuticals 2021, 14(7), 696; <https://doi.org/10.3390/ph14070696> (<https://doi.org/10.3390/ph14070696>) - 19 Jul 2021

Cited by 1 (/1424-8247/14/7/696#citedby) | Viewed by 949

We use cookies on our website to ensure you get the best experience.

Abstract The objective of the present study was to develop *n*-propyl gallate-loaded solid lipid nanoparticles (PG-SLNs) in a hydrogel (HG) formulation using Transcutol-P (TC-P) as a permeation enhancer. Modified solvent injection technique was applied to produce optimized PG-SLNs via the Quality by Design [...] [Read more.](#)

► Show Figures

- [\(/pharmaceuticals/pharmaceuticals-14-00696/article_deploy/html/images/pharmaceuticals-14-00696-ag-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00696/article_deploy/html/images/pharmaceuticals-14-00696-g001-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00696/article_deploy/html/images/pharmaceuticals-14-00696-g002-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00696/article_deploy/html/images/pharmaceuticals-14-00696-g003-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00696/article_deploy/html/images/pharmaceuticals-14-00696-g004-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00696/article_deploy/html/images/pharmaceuticals-14-00696-g005-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00696/article_deploy/html/images/pharmaceuticals-14-00696-g006-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00696/article_deploy/html/images/pharmaceuticals-14-00696-g007-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00696/article_deploy/html/images/pharmaceuticals-14-00696-g008-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00696/article_deploy/html/images/pharmaceuticals-14-00696-g009-550.jpg\)](#)

Open Access Feature Paper Article

☰ ⬇️ (/1424-8247/14/7/695/pdf)

Soluble Angiotensin Converting Enzyme 2 (ACE2) Is Upregulated and Soluble Endothelial Nitric Oxide Synthase (eNOS) Is Downregulated in COVID-19-induced Acute Respiratory Distress Syndrome (ARDS) (/1424-8247/14/7/695)

by [Alice G. Vassiliou](#) (<https://sciprofiles.com/profile/519806>),

[Alexandros Zacharis](#) (<https://sciprofiles.com/profile/author/bW40ZG9mUW5kSIREd1NGK3ByM2NmVC9XbUphQWJSUFh1T2tNWHVCCeZPZz0>),

[Chrysi Keskinidou](#) (<https://sciprofiles.com/profile/1270461>), [Edison Jahaj](#) (<https://sciprofiles.com/profile/1169517>),

[Maria Pratikaki](#) (<https://sciprofiles.com/profile/author/UvNRM1FKelRxcXRMcXFTTRQV3poi8rQ01HQUE2T0ZkRkROMIIMZ20zZz0=>),

[Paris Gallos](#) (<https://sciprofiles.com/profile/1400277>), [Ioanna Dimopoulou](#) (<https://sciprofiles.com/profile/1169424>),

[Anastasia Kotanidou](#) (<https://sciprofiles.com/profile/1337163>) and [Stylianos E. Orfanos](#) (<https://sciprofiles.com/profile/1304179>)

Pharmaceuticals 2021, 14(7), 695; <https://doi.org/10.3390/ph14070695> (<https://doi.org/10.3390/ph14070695>) - 19 Jul 2021

Cited by 4 (/1424-8247/14/7/695#citedby) | Viewed by 975

Abstract A damaged endothelium is an underlying condition of the many complications of COVID-19 patients. The increased mortality risk associated with diseases that have underlying endothelial dysfunction, such as acute respiratory distress syndrome (ARDS), suggests that endothelial (e) nitric oxide synthase (NOS)-derived nitric oxide [...] [Read more.](#)

(This article belongs to the Special Issue [Lung Injury and Repair](#) ([/journal/pharmaceuticals/special_issues/Lung_Injury_Repair](#)))

► Show Figures

- [\(/pharmaceuticals/pharmaceuticals-14-00695/article_deploy/html/images/pharmaceuticals-14-00695-ag-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00695/article_deploy/html/images/pharmaceuticals-14-00695-g001-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00695/article_deploy/html/images/pharmaceuticals-14-00695-g002-550.jpg\)](#)

Open Access Article

☰ ⬇️ (/1424-8247/14/7/694/pdf) ☰

The Effect of Cyanine Dye NK-4 on Photoreceptor Degeneration in a Rat Model of Early-Stage Retinitis Pigmentosa (/1424-8247/14/7/694)

by [Shihui Liu](#) (<https://sciprofiles.com/profile/1658794>), [Toshihiko Matsuo](#) (<https://sciprofiles.com/profile/1601050>),

[Mary Miyaji](#) (<https://sciprofiles.com/profile/author/MUZZSEIyN25HWXRsrKw4ZFR4Tm50VWdhOVliVmZrYjExTDA2S1pCOGJkVT0=>) and

[Osamu Hosoya](#) (<https://sciprofiles.com/profile/author/M0Vwekd0Ly9sZ1pnK25hc0kwJTVXRTNZVndoKzE1Ry9jRXVOUKR5dUxRTT0=>)

Pharmaceuticals 2021, 14(7), 694; <https://doi.org/10.3390/ph14070694> (<https://doi.org/10.3390/ph14070694>) - 19 Jul 2021

Viewed by 1119

Abstract The present study aimed to evaluate the effects of NK-4 on the apoptosis of photoreceptors in a rat model of retinitis pigmentosa and explore the mechanism underlying anti-apoptosis activity. The Royal College of Surgeons (RCS) rats received an intravitreal injection of NK-4 solution [...] [Read more.](#)

(This article belongs to the Special Issue [Advances in Ocular Pharmacology](#) ([/journal/pharmaceuticals/special_issues/ocular_pharmacology](#)))

► Show Figures

- [\(/pharmaceuticals/pharmaceuticals-14-00694/article_deploy/html/images/pharmaceuticals-14-00694-ag-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00694/article_deploy/html/images/pharmaceuticals-14-00694-g001-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00694/article_deploy/html/images/pharmaceuticals-14-00694-g002-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00694/article_deploy/html/images/pharmaceuticals-14-00694-g003-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00694/article_deploy/html/images/pharmaceuticals-14-00694-g004-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00694/article_deploy/html/images/pharmaceuticals-14-00694-g005-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00694/article_deploy/html/images/pharmaceuticals-14-00694-g006-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00694/article_deploy/html/images/pharmaceuticals-14-00694-g007-550.jpg\)](#)

Open Access Article

Accept (/accept_cookies) ☰ ⬇️ (/1424-8247/14/7/693/pdf) ☰

Synthesis and Human Carbonic Anhydrase I, II, IX, and XII Inhibition Studies of Sulphonamides Incorporating Mono-, Bi- and Tricyclic Imide Moieties (/1424-8247/14/7/693)

by [Kalyan K. Sethi](https://sciprofiles.com/profile/1688013) (<https://sciprofiles.com/profile/1688013>), [KM Abha Mishra](https://sciprofiles.com/profile/1701563) (<https://sciprofiles.com/profile/1701563>), [Saurabh M. Verma](https://sciprofiles.com/profile/author/bVNMbHJXdFZwOEF5c1hncFhYTTf4d1N2cVkkQk1WcG9PWFJPbWpWdEFWdz0=) (<https://sciprofiles.com/profile/author/bVNMbHJXdFZwOEF5c1hncFhYTTf4d1N2cVkkQk1WcG9PWFJPbWpWdEFWdz0=>), [Daniela Vullo](https://sciprofiles.com/profile/435867) (<https://sciprofiles.com/profile/435867>), [Fabrizio Carta](https://sciprofiles.com/profile/author/VIFBU3NxTmlLbWxoWHYxemxPRnBLUE9aOfdGVIVBWEgXQ0IveW9DSjhlOD0=) (<https://sciprofiles.com/profile/author/VIFBU3NxTmlLbWxoWHYxemxPRnBLUE9aOfdGVIVBWEgXQ0IveW9DSjhlOD0=>) and [Claudiu T. Supuran](https://sciprofiles.com/profile/11180) (<https://sciprofiles.com/profile/11180>)

Pharmaceuticals 2021, 14(7), 693; <https://doi.org/10.3390/ph14070693> (<https://doi.org/10.3390/ph14070693>) - 19 Jul 2021

Viewed by 716

Abstract New derivatives were synthesised by reaction of amino-containing aromatic sulphonamides with mono-, bi-, and tricyclic anhydrides. These sulphonamides were investigated as human carbonic anhydrases (hCAs, EC 4.2.1.1) I, II, IX, and XII inhibitors. hCA I was inhibited with inhibition constants (K_i) ranging from [...] [Read more](#).

(This article belongs to the Section [Medicinal Chemistry](#) ([/journal/pharmaceuticals/sections/pharm_medical_chemistry](#)))

► **Show Figures**

- [\(/pharmaceuticals/pharmaceuticals-14-00693/article_deploy/html/images/pharmaceuticals-14-00693-g001-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00693/article_deploy/html/images/pharmaceuticals-14-00693-g002-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00693/article_deploy/html/images/pharmaceuticals-14-00693-g003-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00693/article_deploy/html/images/pharmaceuticals-14-00693-g004-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00693/article_deploy/html/images/pharmaceuticals-14-00693-sch001-550.jpg\)](#)

Open Access Review

☰ ⬇️ (/1424-8247/14/7/692/pdf)

Thiophene-Based Compounds with Potential Anti-Inflammatory Activity (/1424-8247/14/7/692)

by [Ryldene Marques Duarte da Cruz](https://sciprofiles.com/profile/235107) (<https://sciprofiles.com/profile/235107>), [Francisco Jaime Bezerra Mendonça-Junior](https://sciprofiles.com/profile/17883) (<https://sciprofiles.com/profile/17883>), [Natália Barbosa de Mélo](https://sciprofiles.com/profile/author/NHZBR1M3QUVlaGJHqNq5Zm9QZWpqcGiwUTizTFc1SWpad09VS0p1RTZocz0) (<https://sciprofiles.com/profile/author/NHZBR1M3QUVlaGJHqNq5Zm9QZWpqcGiwUTizTFc1SWpad09VS0p1RTZocz0>)

, [Luciana Scotti](https://sciprofiles.com/profile/192656) (<https://sciprofiles.com/profile/192656>), [Rodrigo Santos Aquino de Araújo](https://sciprofiles.com/profile/355514) (<https://sciprofiles.com/profile/355514>), [Reinaldo Nóbrega de Almeida](https://sciprofiles.com/profile/author/YmlBay83dUs2TEwWTFhsNnc4MG5nckVMdWh5b3NLRzXnNlpVWtITmc5) (<https://sciprofiles.com/profile/author/YmlBay83dUs2TEwWTFhsNnc4MG5nckVMdWh5b3NLRzXnNlpVWtITmc5>) and

[Ricardo Olímpio de Moura](https://sciprofiles.com/profile/1145298) (<https://sciprofiles.com/profile/1145298>)

Pharmaceuticals 2021, 14(7), 692; <https://doi.org/10.3390/ph14070692> (<https://doi.org/10.3390/ph14070692>) - 19 Jul 2021

Viewed by 784

Abstract Rheumatoid arthritis, arthrosis and gout, among other chronic inflammatory diseases are public health problems and represent major therapeutic challenges. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most prescribed clinical treatments, despite their severe side effects and their exclusive action in improving symptoms, without effectively [...] [Read more](#).

(This article belongs to the Special Issue [Privileged Structures as Leads in Medicinal Chemistry](#) ([/journal/pharmaceuticals/special_issues/privileged_structures](#)))

► **Show Figures**

- [\(/pharmaceuticals/pharmaceuticals-14-00692/article_deploy/html/images/pharmaceuticals-14-00692-g001-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00692/article_deploy/html/images/pharmaceuticals-14-00692-g002-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00692/article_deploy/html/images/pharmaceuticals-14-00692-g003-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00692/article_deploy/html/images/pharmaceuticals-14-00692-g004-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00692/article_deploy/html/images/pharmaceuticals-14-00692-g005-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00692/article_deploy/html/images/pharmaceuticals-14-00692-g006-550.jpg\)](#)
- [\(/pharmaceuticals/pharmaceuticals-14-00692/article_deploy/html/images/pharmaceuticals-14-00692-g007-550.jpg\)](#)

Open Access Perspective

☰ ⬇️ (/1424-8247/14/7/691/pdf)

Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMs) in SARS-CoV-2 Infection (/1424-8247/14/7/691)

by [Gwenolé Loas](https://sciprofiles.com/profile/1473716) (<https://sciprofiles.com/profile/1473716>) and [Pascal Le Corre](https://sciprofiles.com/profile/author/R3hYWENGQ2ZQUFRvQ0ZoZlZS1NhSW9nWFdQnZOSzBKTmRBNmN4WXE4VT0=) (<https://sciprofiles.com/profile/author/R3hYWENGQ2ZQUFRvQ0ZoZlZS1NhSW9nWFdQnZOSzBKTmRBNmN4WXE4VT0=>)

Pharmaceuticals 2021, 14(7), 691; <https://doi.org/10.3390/ph14070691> (<https://doi.org/10.3390/ph14070691>) - 18 Jul 2021

Cited by 2 (/1424-8247/14/7/691#citedby) | Viewed by 1163

Abstract The SARS-CoV-2 outbreak is characterized by the need of the search for curative drugs for treatment. In this paper, we present an *update of knowledge* about the interest of the functional inhibitors of acid sphingomyelinase (FIASMs) in SARS-CoV-2 infection. Forty-nine FIASMs have been [...] [Read more](#).

(This article belongs to the Special Issue [COVID-19 and Pharmaceuticals](#) ([/journal/pharmaceuticals/special_issues/COVID-19_ph](#)))

[Read more about our cookies here](#) ([/about/privacy](#)).

Open Access Review

☰ ⬇️ (/1424-8247/14/7/690/pdf)

Dietary Effects of Anthocyanins in Human Health: A Comprehensive Review (/1424-8247/14/7/690)

Accept ([/accept_cookies](#))

[Back to Top](#)

by [Ana C. Gonçalves \(https://sciprofiles.com/profile/541828\)](https://sciprofiles.com/profile/541828),

[Ana R. Nunes \(https://sciprofiles.com/profile/author/U21idk5jVHFnmWws4QnNxdkiRa2hxeUdJeTQvTHI3RVVJY0JVVWIKK29RWT0=\)](https://sciprofiles.com/profile/author/U21idk5jVHFnmWws4QnNxdkiRa2hxeUdJeTQvTHI3RVVJY0JVVWIKK29RWT0=),

[Amílcar Falcão \(https://sciprofiles.com/profile/author/V0p3MHI0OWtMbjJOTWRTMUpISXUwc2s0YmU4RHE1QWUyWDJKVKEzVGRYND0=\)](https://sciprofiles.com/profile/author/V0p3MHI0OWtMbjJOTWRTMUpISXUwc2s0YmU4RHE1QWUyWDJKVKEzVGRYND0=),

[Gilberto Alves \(https://sciprofiles.com/profile/700070\)](https://sciprofiles.com/profile/700070) and [Luís R. Silva \(https://sciprofiles.com/profile/76010\)](https://sciprofiles.com/profile/76010)

Pharmaceuticals 2021, 14(7), 690; <https://doi.org/10.3390/ph14070690> (<https://doi.org/10.3390/ph14070690>) - 18 Jul 2021

Cited by 2 (1424-8247/14/7/690#citedby) | Viewed by 1193

Abstract In recent years, the consumption of natural-based foods, including beans, fruits, legumes, nuts, oils, vegetables, spices, and whole grains, has been encouraged. This fact is essentially due to their content in bioactive phytochemicals, with the phenolic compounds standing out. Among them, anthocyanins have [...] [Read more.](#)

(This article belongs to the Special Issue [Plant and Marine-Derived Natural Product Research in Drug Discovery: Strengths and Perspective](#) (/journal/pharmaceuticals/special_issues/Plant_Marine))

► [Show Figures](#)

(/pharmaceuticals/pharmaceuticals-14-00690/article_deploy/html/images/pharmaceuticals-14-00690-g001-550.jpg)

(/pharmaceuticals/pharmaceuticals-14-00690/article_deploy/html/images/pharmaceuticals-14-00690-g002-550.jpg)

(/pharmaceuticals/pharmaceuticals-14-00690/article_deploy/html/images/pharmaceuticals-14-00690-g003-550.jpg)

(/pharmaceuticals/pharmaceuticals-14-00690/article_deploy/html/images/pharmaceuticals-14-00690-g004-550.jpg)

(/pharmaceuticals/pharmaceuticals-14-00690/article_deploy/html/images/pharmaceuticals-14-00690-g005-550.jpg)

Open Access Article

☰ ⬇️ (1424-8247/14/7/689/pdf)

Small Molecule–Peptide Conjugates as Dimerization Inhibitors of *Leishmania infantum* Trypanothione Disulfide Reductase (1424-8247/14/7/689)

by [Alejandro Revuelto \(https://sciprofiles.com/profile/1722448\)](https://sciprofiles.com/profile/1722448),

[Isabel López-Martín \(https://sciprofiles.com/profile/author/TFduYzNocUFjVgtJUnlKK2E2WTcWdExsMVh1aWlvS2NFRUc2bVNnaG9Ybz0=\)](https://sciprofiles.com/profile/author/TFduYzNocUFjVgtJUnlKK2E2WTcWdExsMVh1aWlvS2NFRUc2bVNnaG9Ybz0=),

[Héctor de Lucio \(https://sciprofiles.com/profile/1472261\)](https://sciprofiles.com/profile/1472261),

[Juan Carlos García-Soriano \(https://sciprofiles.com/profile/author/S0kvWjI0MzAwcnlBWIZNa0ZGV0E2SjRXa3dHcXF6QzFXcUdEeXQ3\)](https://sciprofiles.com/profile/author/S0kvWjI0MzAwcnlBWIZNa0ZGV0E2SjRXa3dHcXF6QzFXcUdEeXQ3) **OUT**

[Nicola Zanda \(https://sciprofiles.com/profile/1714419\)](https://sciprofiles.com/profile/1714419), [Sonia de Castro \(https://sciprofiles.com/profile/331133\)](https://sciprofiles.com/profile/331133),

[Federico Gago \(https://sciprofiles.com/profile/635938\)](https://sciprofiles.com/profile/635938), [Antonio Jiménez-Ruiz \(https://sciprofiles.com/profile/1491601\)](https://sciprofiles.com/profile/1491601),

[Sonsoles Velázquez \(https://sciprofiles.com/profile/589439\)](https://sciprofiles.com/profile/589439) and [María-José Camarasa \(https://sciprofiles.com/profile/162026\)](https://sciprofiles.com/profile/162026)

Pharmaceuticals 2021, 14(7), 689; <https://doi.org/10.3390/ph14070689> (<https://doi.org/10.3390/ph14070689>) - 17 Jul 2021

Viewed by 922

Abstract Trypanothione disulfide reductase (TryR) is an essential homodimeric enzyme of trypanosomatid parasites that has been validated as a drug target to fight human infections. Using peptides and peptidomimetics, we previously obtained proof of concept that disrupting protein–protein interactions at the dimer interface of [...] [Read more.](#)

(This article belongs to the Special Issue [Drug Discovery and Development for Tropical Diseases \(TDs\)](#) (/journal/pharmaceuticals/special_issues/drug_NTDs))

► [Show Figures](#)

(/pharmaceuticals/pharmaceuticals-14-00689/article_deploy/html/images/pharmaceuticals-14-00689-g001-550.jpg)

(/pharmaceuticals/pharmaceuticals-14-00689/article_deploy/html/images/pharmaceuticals-14-00689-g002-550.jpg)

(/pharmaceuticals/pharmaceuticals-14-00689/article_deploy/html/images/pharmaceuticals-14-00689-g003-550.jpg)

(/pharmaceuticals/pharmaceuticals-14-00689/article_deploy/html/images/pharmaceuticals-14-00689-sch001-550.jpg)

(/pharmaceuticals/pharmaceuticals-14-00689/article_deploy/html/images/pharmaceuticals-14-00689-sch002-550.jpg)

Open Access Article

☰ ⬇️ (1424-8247/14/7/688/pdf) ☰

Conjugation of Diclofenac with Novel Oleanolic Acid Derivatives Modulate Nrf2 and NF-κB Activity in Hepatic Cancer Cells and Normal Hepatocytes Leading to Enhancement of Its Therapeutic and Chemopreventive Potential (1424-8247/14/7/688)

by [Maria Narożna \(https://sciprofiles.com/profile/1376137\)](https://sciprofiles.com/profile/1376137), [Violetta Krajka-Kuźniak \(https://sciprofiles.com/profile/411427\)](https://sciprofiles.com/profile/411427),

[Barbara Bednarczyk-Cwynar \(https://sciprofiles.com/profile/209364\)](https://sciprofiles.com/profile/209364), [Małgorzata Kucińska \(https://sciprofiles.com/profile/1132551\)](https://sciprofiles.com/profile/1132551),

[Robert Kleszcz \(https://sciprofiles.com/profile/1410745\)](https://sciprofiles.com/profile/1410745), [Jacek Kujawski \(https://sciprofiles.com/profile/118156\)](https://sciprofiles.com/profile/118156),

[Hanna Piotrowska-Kempisty \(https://sciprofiles.com/profile/957028\)](https://sciprofiles.com/profile/957028),

[Adam Plewiński \(https://sciprofiles.com/profile/author/OGhJelRVTjZjZi9hNFd2azJYWjNpMzdTTXdoUy9IVE5sR2pVQW00M05xcz0=\)](https://sciprofiles.com/profile/author/OGhJelRVTjZjZi9hNFd2azJYWjNpMzdTTXdoUy9IVE5sR2pVQW00M05xcz0=),

[Marek Murias \(https://sciprofiles.com/profile/929006\)](https://sciprofiles.com/profile/929006) and [Wanda Baer-Dubowska \(https://sciprofiles.com/profile/694331\)](https://sciprofiles.com/profile/694331)

Pharmaceuticals 2021, 14(7), 688; <https://doi.org/10.3390/ph14070688> (<https://doi.org/10.3390/ph14070688>) - 17 Jul 2021

Cited by 2 (1424-8247/14/7/688#citedby) | Viewed by 1179

Abstract Combining NSAIDs with conventional therapeutics was recently explored as a new strategy in cancer therapy. Our earlier studies showed that novel oleanolic acid oximes (OAO) conjugated with aspirin or indomethacin may enhance their anti-cancer potential through modulation of the Nrf2 and NF-κB signaling [...] [Read more.](#)

(This article belongs to the Collection [Old Pharmaceuticals with New Applications](#) (/journal/pharmaceuticals/special_issues/Oldpharm_newappli))
Read more about our cookies [here](#) ([about/privacy](#)).

► [Show Figures](#)



Accept (/accept_cookies)

Back to Top

 (/pharmaceuticals/pharmaceuticals-14-00688/article_deploy/html/images/pharmaceuticals-14-00688-ag-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00688/article_deploy/html/images/pharmaceuticals-14-00688-g001-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00688/article_deploy/html/images/pharmaceuticals-14-00688-g002-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00688/article_deploy/html/images/pharmaceuticals-14-00688-g003-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00688/article_deploy/html/images/pharmaceuticals-14-00688-g004-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00688/article_deploy/html/images/pharmaceuticals-14-00688-g005-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00688/article_deploy/html/images/pharmaceuticals-14-00688-g006-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00688/article_deploy/html/images/pharmaceuticals-14-00688-g007-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00688/article_deploy/html/images/pharmaceuticals-14-00688-g008-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00688/article_deploy/html/images/pharmaceuticals-14-00688-g009-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00688/article_deploy/html/images/pharmaceuticals-14-00688-g010-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00688/article_deploy/html/images/pharmaceuticals-14-00688-g011-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00688/article_deploy/html/images/pharmaceuticals-14-00688-g012-550.jpg)




Open Access Review

  (/1424-8247/14/7/687/pdf)

Investigating Potential Applications of the Fish Anti-Microbial Peptide Pleurocidin: A Systematic Review (/1424-8247/14/7/687)

by

 **Katelyn A. M. McMillan** (<https://sciprofiles.com/profile/author/NHhrbUM2ZEhOaXZRSFZEQ21PNTIvanZSU1hQckVOanNTSVFma2dHRVNXOD0=>)
and

 **Melanie R. Power Coombs** (<https://sciprofiles.com/profile/628301>)

Pharmaceuticals **2021**, *14*(7), 687; <https://doi.org/10.3390/ph14070687> (<https://doi.org/10.3390/ph14070687>) - 17 Jul 2021

Viewed by 971



Abstract The anti-microbial peptide (AMP) pleurocidin is found in winter flounder (*Pseudopleuronectes americanus*), an Atlantic flounder species. There is promising evidence for clinical, aquaculture, and veterinary applications of pleurocidin. This review provides an overview of the current literature available on pleurocidin to [...] [Read more](#).

(This article belongs to the Special Issue **Antimicrobial Peptides as New Weapons to Fight Antimicrobial Resistance** (/journal/pharmaceuticals/special_issues/Antimicrobial_Peptides_Weapons))

► Show Figures


(/pharmaceuticals/pharmaceuticals-14-00687/article_deploy/html/images/pharmaceuticals-14-00687-ag-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00687/article_deploy/html/images/pharmaceuticals-14-00687-g001-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00687/article_deploy/html/images/pharmaceuticals-14-00687-g002-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00687/article_deploy/html/images/pharmaceuticals-14-00687-g003-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00687/article_deploy/html/images/pharmaceuticals-14-00687-g004-550.jpg)

Open Access Article

  (/1424-8247/14/7/686/pdf)

Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite *Schistosoma mansoni* (/1424-8247/14/7/686)

by  **Raquel Porto** (<https://sciprofiles.com/profile/author/QzNpNjFMMGlzZGhuald1UG85L2dJdis5QWx4cXBCbUVIOHNZaDeRWd1VT0=>),



 **Ana C. Mengarda** (<https://sciprofiles.com/profile/1719352>),

 **Rayssa A. Cajas** (<https://sciprofiles.com/profile/author/Z2xWL3UzL1VjNDRnSGo5VXA1OHBPnFpzZXc2RlVvaEt1WkpJQ3J1TXRidz0=>),

 **Maria C. Salvadori** (<https://sciprofiles.com/profile/author/R29ranVWU0ZaWHc1a1FCZnNFZ1JBQ0dJSElInNlqRWlJa3VRd1MrTmphMD0=>),

 **Fernanda S. Teixeira** (<https://sciprofiles.com/profile/525445>),  **Daniel D. R. Arcanjo** (<https://sciprofiles.com/profile/59298>),

 **Abolghasem Siyadatpanah** (<https://sciprofiles.com/profile/1188190>),  **Maria de Lourdes Pereira** (<https://sciprofiles.com/profile/293355>),

 **Poirat Wilairatana** (<https://sciprofiles.com/profile/1588691>) and  **Josué de Moraes** (<https://sciprofiles.com/profile/1679616>)

Pharmaceuticals **2021**, *14*(7), 686; <https://doi.org/10.3390/ph14070686> (<https://doi.org/10.3390/ph14070686>) - 16 Jul 2021

Cited by 2 (</1424-8247/14/7/686#citedby>) | Viewed by 889

Abstract The intravascular parasitic worm *Schistosoma mansoni* is a causative agent of schistosomiasis, a disease of great global public health significance. Praziquantel is the only drug available to treat schistosomiasis and there is an urgent demand for new anthelmintic agents. Adopting a phenotypic drug [...] [Read more](#).

(This article belongs to the Special Issue **Antiparasitics** (/journal/pharmaceuticals/special_issues/antiparasitics))

► Show Figures

(/pharmaceuticals/pharmaceuticals-14-00686/article_deploy/html/images/pharmaceuticals-14-00686-g001-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00686/article_deploy/html/images/pharmaceuticals-14-00686-g002-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00686/article_deploy/html/images/pharmaceuticals-14-00686-g003-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00686/article_deploy/html/images/pharmaceuticals-14-00686-g004-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00686/article_deploy/html/images/pharmaceuticals-14-00686-g005-550.jpg)
(/pharmaceuticals/pharmaceuticals-14-00686/article_deploy/html/images/pharmaceuticals-14-00686-g006-550.jpg)

We use cookies on our website to ensure you get the best experience.

[Read more about our cookies here \(about:cookies\)](#)

Accept (/accept_cookies)

[Back to Top](#)

Interaction between DNA, Albumin and Apo-Transferrin and Iridium(III) Complexes with Phosphines Derived from Fluoroquinolones as a Potent Anticancer Drug (1424-8247/14/7/685)

by  [Sandra Amanda Koziel](https://sciprofiles.com/profile/1684286) (<https://sciprofiles.com/profile/1684286>),  [Monika Katarzyna Lesiów](https://sciprofiles.com/profile/1561886) (<https://sciprofiles.com/profile/1561886>),  [Daria Wojtala](https://sciprofiles.com/profile/1719329) (<https://sciprofiles.com/profile/1719329>),  [Edyta Dyguda-Kazimierowicz](https://sciprofiles.com/profile/448150) (<https://sciprofiles.com/profile/448150>),  [Dariusz Bieńko](https://sciprofiles.com/profile/author/MHgwRVJDT3Fya29pZjJPZnBtdXZibW4zTUtdVE4xSUY1cHJma1ZlQUxxYz0=) (<https://sciprofiles.com/profile/author/MHgwRVJDT3Fya29pZjJPZnBtdXZibW4zTUtdVE4xSUY1cHJma1ZlQUxxYz0=>) and  [Urszula Katarzyna Komarnicka](https://sciprofiles.com/profile/1561885) (<https://sciprofiles.com/profile/1561885>)

Pharmaceuticals 2021, 14(7), 685; <https://doi.org/10.3390/ph14070685> (<https://doi.org/10.3390/ph14070685>) - 16 Jul 2021

Cited by 1 ([1424-8247/14/7/685#citedby](#)) | Viewed by 874

Abstract A group of cytotoxic half-sandwich iridium(III) complexes with aminomethyl(diphenyl)phosphine derived from fluoroquinolone antibiotics exhibit the ability to (i) accumulate in the nucleus, (ii) induce apoptosis, (iii) activate caspase-3/7 activity, (iv) induce the changes in cell cycle leading to G2/M phase arrest, and (v) [...] [Read more.](#)




(This article belongs to the Special Issue **Privileged Structures as Leads in Medicinal Chemistry** (

[/journal/pharmaceuticals/special_issues/privileged_structures](#).)

► **Show Figures**

[\(/pharmaceuticals/pharmaceuticals-14-00685/article_deploy/html/images/pharmaceuticals-14-00685-ag-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00685/article_deploy/html/images/pharmaceuticals-14-00685-g001-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00685/article_deploy/html/images/pharmaceuticals-14-00685-g002-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00685/article_deploy/html/images/pharmaceuticals-14-00685-g003-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00685/article_deploy/html/images/pharmaceuticals-14-00685-g004-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00685/article_deploy/html/images/pharmaceuticals-14-00685-g005-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00685/article_deploy/html/images/pharmaceuticals-14-00685-g006-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00685/article_deploy/html/images/pharmaceuticals-14-00685-g007-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00685/article_deploy/html/images/pharmaceuticals-14-00685-g008-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00685/article_deploy/html/images/pharmaceuticals-14-00685-g009-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00685/article_deploy/html/images/pharmaceuticals-14-00685-g010-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00685/article_deploy/html/images/pharmaceuticals-14-00685-g011-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00685/article_deploy/html/images/pharmaceuticals-14-00685-sch001-550.jpg\)](#)

Delaying Effects of Prolactin and Growth Hormone on Aging Processes in Bovine Oocytes Matured In Vitro (1424-8247/14/7/684)

by  [Galina N. Singina](https://sciprofiles.com/profile/author/ZFppWIZzSEFBemtGMXkxVmJBdUVqeURkell5VkpJTit4bHAzbFhIMXhzQT0=) (<https://sciprofiles.com/profile/author/ZFppWIZzSEFBemtGMXkxVmJBdUVqeURkell5VkpJTit4bHAzbFhIMXhzQT0=>),  [Ekaterina N. Shedova](https://sciprofiles.com/profile/author/TTluKzIKOEtAOfdJTDJPUeZnZUG2ZlDaOEIWIi82ZTYzMO9pRmkxWXZRST0=) (<https://sciprofiles.com/profile/author/TTluKzIKOEtAOfdJTDJPUeZnZUG2ZlDaOEIWIi82ZTYzMO9pRmkxWXZRST0=>),  [Alexander V. Lopukhov](https://sciprofiles.com/profile/author/N3lGdXfWRVRVvtQVCtQL0swZ0rQVJ6dkiwZksWMEZsV29UV0ZKSvo4az0=) (<https://sciprofiles.com/profile/author/N3lGdXfWRVRVvtQVCtQL0swZ0rQVJ6dkiwZksWMEZsV29UV0ZKSvo4az0=>),  [Olga S. Mityashova](https://sciprofiles.com/profile/author/SFkzVENjbxRkUnAvYk1XbEp0aFNZOU84YWIWDMDZld29qT1pnYko0WDRaaz0=) (<https://sciprofiles.com/profile/author/SFkzVENjbxRkUnAvYk1XbEp0aFNZOU84YWIWDMDZld29qT1pnYko0WDRaaz0=>) and

 [Irina Y. Lebedeva](https://sciprofiles.com/profile/1665692) (<https://sciprofiles.com/profile/1665692>)

Pharmaceuticals 2021, 14(7), 684; <https://doi.org/10.3390/ph14070684> (<https://doi.org/10.3390/ph14070684>) - 16 Jul 2021

Viewed by 877

Abstract Aging processes accelerate dramatically in oocytes that have reached the metaphase-II (M-II) stage. The present work aimed to study the patterns and intracellular pathways of actions of prolactin (PRL) and growth hormone (GH) on age-associated changes in bovine M-II oocytes aging in vitro. [...] [Read more.](#)

(This article belongs to the Special Issue **Novel Regulators of Female Reproduction** (

[/journal/pharmaceuticals/special_issues/female_reproduction](#).)

► **Show Figures**

[\(/pharmaceuticals/pharmaceuticals-14-00684/article_deploy/html/images/pharmaceuticals-14-00684-ag-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00684/article_deploy/html/images/pharmaceuticals-14-00684-g001-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00684/article_deploy/html/images/pharmaceuticals-14-00684-g002-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00684/article_deploy/html/images/pharmaceuticals-14-00684-g003-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00684/article_deploy/html/images/pharmaceuticals-14-00684-g004-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00684/article_deploy/html/images/pharmaceuticals-14-00684-g005-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00684/article_deploy/html/images/pharmaceuticals-14-00684-g006-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00684/article_deploy/html/images/pharmaceuticals-14-00684-g007-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00684/article_deploy/html/images/pharmaceuticals-14-00684-g008-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00684/article_deploy/html/images/pharmaceuticals-14-00684-g009-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00684/article_deploy/html/images/pharmaceuticals-14-00684-g010-550.jpg\)](#)

[\(/pharmaceuticals/pharmaceuticals-14-00684/article_deploy/html/images/pharmaceuticals-14-00684-g011-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00684/article_deploy/html/images/pharmaceuticals-14-00684-g012-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00684/article_deploy/html/images/pharmaceuticals-14-00684-g013-550.jpg\)](#)



Open Access Article

[\(/1424-8247/14/7/683/pdf\)](#)

Efficacy of an Anti-Cellulite Herbal Emgel: A Randomized Clinical Trial ([/1424-8247/14/7/683](#))

by [Ngamrayu Ngamdokmai](#) (<https://sciprofiles.com/profile/1486090>), [Neti Waranuch](#) (<https://sciprofiles.com/profile/1267207>),
 [Krongkarn Chootip](#) (<https://sciprofiles.com/profile/595320>), [Katechan Jampachaisri](#) (<https://sciprofiles.com/profile/851940>),
 [C. Norman Scholfield](#) (<https://sciprofiles.com/profile/1717644>) and [Kornkanok Ingkaninan](#) (<https://sciprofiles.com/profile/763641>)

Pharmaceuticals 2021, 14(7), 683; <https://doi.org/10.3390/ph14070683> (<https://doi.org/10.3390/ph14070683>) - 16 Jul 2021

Cited by 1 ([/1424-8247/14/7/683#citedby](#)) | Viewed by 1170

Abstract Cellulite describes unsightly skin overlying subcutaneous fat around thighs and buttocks of post-pubescent females. A herbal 'emgel' containing volatile oils and extracts of A traditional Thai herbal compress was tested in a double-blind, placebo-controlled trial with 18 women aged 20–50 year with severe [...] [Read more.](#)

(This article belongs to the Special Issue [Promising Anti-inflammatory Medicinal Plants—An Assessment of Bioavailability, Pharmacokinetics, Clinical Efficacy and Overview of New Methodological Approaches](#) ([/journal/pharmaceuticals/special_issues/Anti-inflammatory_Plants](#)))

► Show Figures

[\(/pharmaceuticals/pharmaceuticals-14-00683/article_deploy/html/images/pharmaceuticals-14-00683-g001-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00683/article_deploy/html/images/pharmaceuticals-14-00683-g002-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00683/article_deploy/html/images/pharmaceuticals-14-00683-g003-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00683/article_deploy/html/images/pharmaceuticals-14-00683-g004-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00683/article_deploy/html/images/pharmaceuticals-14-00683-g005-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00683/article_deploy/html/images/pharmaceuticals-14-00683-g006-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00683/article_deploy/html/images/pharmaceuticals-14-00683-g007-550.jpg\)](#)



Open Access Article

[\(/1424-8247/14/7/682/pdf\)](#)

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy ([/1424-8247/14/7/682](#))

by [Jianling Bi](#) (<https://sciprofiles.com/profile/1798237>), [Garima Dixit](#) (<https://sciprofiles.com/profile/1421851>),
 [Yuping Zhang](#) (<https://sciprofiles.com/profile/author/UjhGc2lzSUV0bGdwTmZseVpVNU1PVXh5bDU4NWN4a0lSeU50M0VNNGxzWT0=>),
 [Eric J. Devor](#) (<https://sciprofiles.com/profile/1043616>),
 [Haley A. Losh](#) (<https://sciprofiles.com/profile/author/eENFQ0pDMjBIYkxQZklpZGtLSTJUQ0RwbkoreTdpNUZ1TVNEYTVjenJkaz0=>),
 [Andreea M. Newton](#) (<https://sciprofiles.com/profile/1371861>),
 [Kristen L. Coleman](#) (<https://sciprofiles.com/profile/author/OV0tneVMvMFdzTzJpNnQrSjFZOvdmck5BSSt0bWVLYkc4TXdjUWRhTudUdz0=>),
 [Donna A. Santillan](#) (<https://sciprofiles.com/profile/author/V0tneVMvMFdzTzJpNnQrSjFZOvdmck5BSSt0bWVLYkc4TXdjUWRhTudUdz0=>),
 [Thorsten Maretzky](#) (<https://sciprofiles.com/profile/994602>), [Kristina W. Thiel](#) (<https://sciprofiles.com/profile/803766>) and
 [Kimberly K. Leslie](#) (<https://sciprofiles.com/profile/53832>)

Pharmaceuticals 2021, 14(7), 682; <https://doi.org/10.3390/ph14070682> (<https://doi.org/10.3390/ph14070682>) - 16 Jul 2021

Viewed by 831

Abstract Angiogenesis plays a crucial role in tumor development and metastasis. Both bevacizumab and cediranib have demonstrated activity as single anti-angiogenic agents in endometrial cancer, though subsequent studies of bevacizumab combined with chemotherapy failed to improve outcomes compared to chemotherapy alone. Our objective was [...] [Read more.](#)

(This article belongs to the Special Issue [Common Mutations in Gynecologic Cancers](#) ([/journal/pharmaceuticals/special_issues/TP53_Gynecologic_Cancers](#)))

► Show Figures

[\(/pharmaceuticals/pharmaceuticals-14-00682/article_deploy/html/images/pharmaceuticals-14-00682-ag-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00682/article_deploy/html/images/pharmaceuticals-14-00682-g001-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00682/article_deploy/html/images/pharmaceuticals-14-00682-g002-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00682/article_deploy/html/images/pharmaceuticals-14-00682-g003-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00682/article_deploy/html/images/pharmaceuticals-14-00682-g004-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00682/article_deploy/html/images/pharmaceuticals-14-00682-g005-550.jpg\)](#)
[\(/pharmaceuticals/pharmaceuticals-14-00682/article_deploy/html/images/pharmaceuticals-14-00682-g006-550.jpg\)](#)

Open Access Article

[\(/1424-8247/14/7/681/pdf\)](#)

We use cookies on our website to ensure you get the best experience. **Comprehensive Analysis of Chemotherapeutic Agents That Induce Infectious Neutropenia** ([/1424-8247/14/7/681](#))


[Read more about our cookies here](#) ([/about/privacy](#)).

by [Mashiro Okunaka](#) (<https://sciprofiles.com/profile/1551960>), [Daisuke Kano](#) (<https://sciprofiles.com/profile/1579096>),

[Reiko Matsui](#) (<https://sciprofiles.com/profile/author/dndROXd4ZE53KzBsVjZ3MUNPvWNFTDIrcnp4SHZQWktBOVkoNG5LQIV3ND0=>),

Accept ([/accept_cookies](#))

[Back to Top](#)

Toshikatsu Kawasaki (<https://sciprofiles.com/profile/author/MzV0ZGVnQ0JWT3NCQmd3NGlmaTk5NGFWR24zY0FkZ3NvY281L1Q2ZW4wVT0=>) and 

Yoshihiro Uesawa (<https://sciprofiles.com/profile/253868>)

Pharmaceuticals 2021, 14(7), 681; <https://doi.org/10.3390/ph14070681> (<https://doi.org/10.3390/ph14070681>) - 15 Jul 2021

Viewed by 656



Abstract Chemotherapy-induced neutropenia (CIN) has been associated with a risk of infections and chemotherapy dose reductions and delays. The chemotherapy regimen remains one of the primary determinants of the risk of neutropenia, with some regimens being more myelotoxic than others. Although a number of [...] [Read more.](#)

(This article belongs to the Special Issue [Cancer Drugs Treatment and Toxicity \(/journal/pharmaceuticals/special_issues/AntiCancer_Toxicity \)](#))

► **Show Figures**

[\(/pharmaceuticals/pharmaceuticals-14-00681/article_deploy/html/images/pharmaceuticals-14-00681-g001-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00681/article_deploy/html/images/pharmaceuticals-14-00681-g001-550.jpg)

[\(/pharmaceuticals/pharmaceuticals-14-00681/article_deploy/html/images/pharmaceuticals-14-00681-g002-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00681/article_deploy/html/images/pharmaceuticals-14-00681-g002-550.jpg)


[\(/pharmaceuticals/pharmaceuticals-14-00681/article_deploy/html/images/pharmaceuticals-14-00681-g003-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00681/article_deploy/html/images/pharmaceuticals-14-00681-g003-550.jpg)

[\(/pharmaceuticals/pharmaceuticals-14-00681/article_deploy/html/images/pharmaceuticals-14-00681-g004-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00681/article_deploy/html/images/pharmaceuticals-14-00681-g004-550.jpg)

[\(/pharmaceuticals/pharmaceuticals-14-00681/article_deploy/html/images/pharmaceuticals-14-00681-g005-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00681/article_deploy/html/images/pharmaceuticals-14-00681-g005-550.jpg)

[\(/pharmaceuticals/pharmaceuticals-14-00681/article_deploy/html/images/pharmaceuticals-14-00681-g006-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00681/article_deploy/html/images/pharmaceuticals-14-00681-g006-550.jpg)



Open Access Review






Current Status of Baricitinib as a Repurposed Therapy for COVID-19 (/1424-8247/14/7/680)

by  Maha Saber-Ayad (<https://sciprofiles.com/profile/436027>),

 Sarah Hammoudeh (<https://sciprofiles.com/profile/author/NzEybE94KzdTNUVGS25SNU9RTHFZZGjSnEwODc0V0xsWmdkdGhOUluzaz0=>),

 Eman Abu-Gharbieh (<https://sciprofiles.com/profile/435254>),  Rifat Hamoudi (<https://sciprofiles.com/profile/699633>),

 Hamadeh Tarazi (<https://sciprofiles.com/profile/author/YmVYT1d5am9YS2JGREZ0S0E3N0JYNHpyNK1jNHdISWdpMctySm9xMFA3RT0=>),

 Taleb H. Al-Tel (<https://sciprofiles.com/profile/953827>) and  Qutayba Hamid (<https://sciprofiles.com/profile/1098229>)

Pharmaceuticals 2021, 14(7), 680; <https://doi.org/10.3390/ph14070680> (<https://doi.org/10.3390/ph14070680>) - 15 Jul 2021

Viewed by 1387

Abstract The emergence of the COVID-19 pandemic has mandated the instant (re)search for potential drug candidates. In response to the unprecedented situation, it was recognized early that repurposing of available drugs in the market could timely save lives, by skipping the lengthy phases of [...] [Read more.](#)

(This article belongs to the Special Issue [COVID-19 in Pharmaceuticals \(/journal/pharmaceuticals/special_issues/COVID-19_ph \)](#))

► **Show Figures**

[\(/pharmaceuticals/pharmaceuticals-14-00680/article_deploy/html/images/pharmaceuticals-14-00680-g001-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00680/article_deploy/html/images/pharmaceuticals-14-00680-g001-550.jpg)


[\(/pharmaceuticals/pharmaceuticals-14-00680/article_deploy/html/images/pharmaceuticals-14-00680-g002-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00680/article_deploy/html/images/pharmaceuticals-14-00680-g002-550.jpg)

[\(/pharmaceuticals/pharmaceuticals-14-00680/article_deploy/html/images/pharmaceuticals-14-00680-g003-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00680/article_deploy/html/images/pharmaceuticals-14-00680-g003-550.jpg)

[\(/pharmaceuticals/pharmaceuticals-14-00680/article_deploy/html/images/pharmaceuticals-14-00680-g004-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00680/article_deploy/html/images/pharmaceuticals-14-00680-g004-550.jpg)


[\(/pharmaceuticals/pharmaceuticals-14-00680/article_deploy/html/images/pharmaceuticals-14-00680-g005-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00680/article_deploy/html/images/pharmaceuticals-14-00680-g005-550.jpg)

Open Access Article





Suppression of Intracellular Reactive Oxygen Species in Human Corneal Epithelial Cells via the Combination of Quercetin Nanoparticles and Epigallocatechin Gallate and In Situ Thermosensitive Gel Formulation for Ocular Drug Delivery (/1424-8247/14/7/679)

by  Chuda Chittasupho (<https://sciprofiles.com/profile/1308444>),  Taepin Junmahasathien (<https://sciprofiles.com/profile/1671921>),

 Jiratchaya Chalermmongkol (<https://sciprofiles.com/profile/author/TVdkZ0JDZXBZTGERZFdUSlpmL1lwNUZiNkp6dXJhMmN0MEFGUTNSc3Zrt>),

 Raksakul Wongjirasakul (<https://sciprofiles.com/profile/author/cDdtcHIBYjhUTkiUN1JLZTJXa2ZzdmRLSFBUZjFQbm9Fdl1BNW9ZakJVdz0=>),

 Phuriwat Leesawat (<https://sciprofiles.com/profile/author/eStBS0tNTkw3dDMzNExSWDM3aFVHSTBleXlyUjMxLzdMN2piYnRRrElvdz0=>) and

 Siriporn Okonogi (<https://sciprofiles.com/profile/210399>)

Pharmaceuticals 2021, 14(7), 679; <https://doi.org/10.3390/ph14070679> (<https://doi.org/10.3390/ph14070679>) - 15 Jul 2021

Cited by 1 (/1424-8247/14/7/679#citedby) | Viewed by 908

Abstract Oxidative stress can cause several severe ophthalmological diseases. In this study, we developed a thermosensitive gel as a delivery system for two antioxidant substances, namely, quercetin and epigallocatechin gallate. The quercetin was loaded in the PLGA nanoparticles using a solvent displacement method. The [...] [Read more.](#)

(This article belongs to the Section [Pharmaceutical Technology \(/journal/pharmaceuticals/sections/pharmaceutical_technology \)](#))

► **Show Figures**

[\(/pharmaceuticals/pharmaceuticals-14-00679/article_deploy/html/images/pharmaceuticals-14-00679-g001-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00679/article_deploy/html/images/pharmaceuticals-14-00679-g001-550.jpg)

[\(/pharmaceuticals/pharmaceuticals-14-00679/article_deploy/html/images/pharmaceuticals-14-00679-g002-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00679/article_deploy/html/images/pharmaceuticals-14-00679-g002-550.jpg)

[\(/pharmaceuticals/pharmaceuticals-14-00679/article_deploy/html/images/pharmaceuticals-14-00679-g003-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00679/article_deploy/html/images/pharmaceuticals-14-00679-g003-550.jpg)

[\(/pharmaceuticals/pharmaceuticals-14-00679/article_deploy/html/images/pharmaceuticals-14-00679-g004-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00679/article_deploy/html/images/pharmaceuticals-14-00679-g004-550.jpg)

[\(/pharmaceuticals/pharmaceuticals-14-00679/article_deploy/html/images/pharmaceuticals-14-00679-g005-550.jpg\)](/pharmaceuticals/pharmaceuticals-14-00679/article_deploy/html/images/pharmaceuticals-14-00679-g005-550.jpg)

Accept (/accept_cookies)

Back to TopTop



Review

Signaling Pathway and Transcriptional Regulation in Osteoblasts during Bone Healing: Direct Involvement of Hydroxyapatite as a Biomaterial

Junaidi Khotib ^{1,*}, Maria Apriliani Gani ², Aniek Setiya Budiatin ¹, Maria Lucia Ardhani Dwi Lestari ³, Erreza Rahadiansyah ^{4,5} and Chrismawan Ardianto ¹

- ¹ Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia; anieksb@yahoo.co.id (A.S.B.); chrismawan-a@ff.unair.ac.id (C.A.)
- ² Doctoral Programme of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia; maria.apriliani.gani-2019@ff.unair.ac.id
- ³ Department of Pharmaceutical Science, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia; maria-lestari@ff.unair.ac.id
- ⁴ Department of Orthopaedics, Faculty of Medicine, Universitas Airlangga, Surabaya 60132, Indonesia; rahadiansyah@fk.unair.ac.id
- ⁵ Department of Orthopedic and Traumatology, Faculty of Medicine, Airlangga University Teaching Hospital, Surabaya 60115, Indonesia
- * Correspondence: junaidi-k@ff.unair.ac.id; Tel.: +62-813-318-40710



Citation: Khotib, J.; Gani, M.A.; Budiatin, A.S.; Lestari, M.L.A.D.; Rahadiansyah, E.; Ardianto, C. Signaling Pathway and Transcriptional Regulation in Osteoblasts during Bone Healing: Direct Involvement of Hydroxyapatite as a Biomaterial. *Pharmaceuticals* **2021**, *14*, 615. <https://doi.org/10.3390/ph14070615>

Academic Editor: Olaf-Georg Issinger

Received: 12 May 2021

Accepted: 23 June 2021

Published: 26 June 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Bone defects and periodontal disease are pathological conditions that may become neglected diseases if not treated properly. Hydroxyapatite (HA), along with tricalcium phosphate and bioglass ceramic, is a biomaterial widely applied to orthopedic and dental uses. The in vivo performance of HA is determined by the interaction between HA particles with bone cells, particularly the bone mineralizing cells osteoblasts. It has been reported that HA-induced osteoblastic differentiation by increasing the expression of osteogenic transcription factors. However, the pathway involved and the events that occur in the cell membrane have not been well understood and remain controversial. Advances in gene editing and the discovery of pharmacologic inhibitors assist researchers to better understand osteoblastic differentiation. This review summarizes the involvement of extracellular signal-regulated kinase (ERK), p38, Wnt, and bone morphogenetic protein 2 (BMP2) in osteoblastic cellular regulation induced by HA. These advances enhance the current understanding of the molecular mechanism of HA as a biomaterial. Moreover, they provide a better strategy for the design of HA to be utilized in bone engineering.

Keywords: neglected diseases; osteoblast transcription factors; osteoblast signaling pathway; Runx2; ERK; p38; Wnt; BMP; osteoblast differentiation

1. Introduction

Hydroxyapatite (HA) is a biomaterial used for the production of orthopedic and dental implants. Typically, HA is used as a single material or composite in combination with other materials [1–3], a coating agent for bone graft [1,4,5], and a matrix for drug delivery systems targeting bone tissue [6]. HA is widely used because it contains similar physical and chemical components to those of natural HA present in bone tissue [2]. Moreover, studies reported that HA induced a favorable immune response [7], exerted an angiogenic effect on defective bone tissue [8,9], and activated osteoblasts and osteoclasts for bone tissue remodeling by accelerating the differentiation of these cells [10,11].

Osteoblasts are cells that play important roles in bone tissue repair. They increase bone growth at the defect area by synthesizing bone matrix, which is subsequently mineralized [12]. Prior to that, osteoblasts must be differentiated from their precursors. Several transcription factors are vital in osteoblastic differentiation, such as the master transcription

factor Runt-related transcription factor 2 (Runx2) and its downstream osterix (Osx) [13,14], activating transcription factor 4 (ATF4) [15], distal-less homeobox 5 (Dlx5) [16], msh homeobox 1 (Msx-1) [17], and Msx-2 [18], and they are responsible for the expression of osteoblast proteins, including alkaline phosphatase (ALP) [19], collagen, and noncollagenous proteins [20–25]. These transcription factors are commonly used as markers in studies involving osteoblastic differentiation, including those related to the use of HA for bone regeneration [26–28].

Before inducing changes in gene expression in a particular cell, a stimulator, (e.g., HA) activates a signaling pathway. Understanding the role of signaling pathways in cellular regulation helps to determine the physiological basis and identify new therapeutic strategies [7,28]. Several studies reported that the changes in transcription factors induced by HA are mediated by several signaling pathways, for instance, the mitogen-activated protein kinases (MAPK), Wnt, and bone morphogenetic protein (BMP) signaling pathways [26–28]. Furthermore, studies also reported that the physical characteristics of HA are also important in determining the cellular mechanism of the osteoblast lineage. Reportedly, differences in HA sizes and particle shapes activated a particular signaling pathway and upregulated specific transcription factors [28]. This also occurred due to the surface topography of HA [26]. This review discusses the signaling pathway and transcription factors associated with osteoblastic differentiation induced by HA. The available evidence enhances the current understanding of the molecular mechanisms of HA as a biomaterial, and provides a better strategy for the design of HA to be utilized in bone tissue regeneration.

2. HA

HA ($\text{Ca}_{10}[\text{PO}_4]_6[\text{OH}]_2$) is a derivate of calcium phosphate along with tricalcium phosphate and bioglass ceramic [29]. Calcium phosphate is often used as a biomaterial for the production of bone and dental tissue implants, or as a drug delivery system targeting hard tissue [2,6,9,30]. The organic and inorganic components account for 40% and 60% of the extracellular matrix (ECM) of bone, respectively. The organic component of bone tissue consists of 90% type I collagen (COL1) and 10% noncollagenous protein, whereas the inorganic part consists of bone HA [31]. This renders HA the most suitable biomaterial for bone regeneration [2].

HA possesses biocompatible, biodegradable, osteoconductive, and osteoinductive properties. It is biocompatible because its chemical and physical properties resemble those of natural HA in bone [31]. The biodegradable nature of HA is attributed to its slow degradation when used *in vivo*, following the growth of new bone tissue [9]. Furthermore, HA also functions as a scaffold to bone tissue, making it osteoconductive, especially with collagen or gelatin. As a composite with collagen or gelatin, HA exhibits similar compressive and tensile strength to that of human bones. These composites also mimic the inorganic-organic component naturally present in bone [11,32]. In addition, HA is an osteoinductive material able to induce osteogenesis, particularly when combined with growth factors and osteogenic cells [33].

The beneficial properties of HA contributed to the *in vivo* performance compared to other biomaterials. HA extracted from bovine bone caused higher blood vessel formation than tricalcic phosphate and periglass *in vivo* [34]. HA also supported new bone growth compared to β -TCP *in vivo* [35]. Moreover, a study by Lee et al. reported that HA caused greater expression of the ALP and COL1 encoding genes than calcium metaphosphate in a mouse intramuscular defect model [36].

Based on a retrospective radiological study, osteointegration occurred in cranial hydroxyapatite implants to a degree of more than 50% [37]. Furthermore, based on clinical data, HA-coated implants consistently had higher cumulative survival rates at upper molar sites than titanium-coated implants until eight years after placement [38]. Similar results were found in the study by Pieske et al. in which HA-coated pins in external fixators applied for unstable fractures showed a trend towards a superior clinical outcome compared to stainless steel pins [39]. Moreover, another clinical study reported that the application

of nanocrystalline HA in human intrabony periodontal defects resulted in improved soft and hard tissue parameters after six months. This was as effective as the use of autogenous bone graft, which is recognized as the gold standard in clinical uses [40]. Therefore, further study and sustainable use of HA have excellent potential in clinical uses.

HA is obtained through synthesis from calcium and phosphate or extraction from natural materials. Synthesis is performed via wet, dry, or high-temperature methods. Each method produces HA with different sizes, morphology, and a calcium-to-phosphorous (Ca/P) ratio [41]. These characteristics are important in determining the compatibility and osteoconductivity of HA when used as a biomaterial. For example, the Ca/P ratio of biomaterials should be similar to that naturally present in bone, which is 1.67 [42]. Compared to other materials, HA possesses great characteristics. For example, HA had greater mechanical strength compared to β -TCP, making it resistant to premature degradation in vivo [35]. Furthermore, the addition of HA to a particular scaffold resulted in greater tensile strength compared to the addition of silica [43].

HA is also obtained from natural sources through extraction from mammals (bovine, camel, and horse), fish and shells, or plants and algae [44]. Mammals, such as bovine, are the most common source of HA owing to its abundance in their bones. Moreover, the chemical content of HA extracted from bovine bone (termed bovine HA) is similar to that of human bones. This renders bovine-HA-based implants suitable for orthopedic and dental uses [2,45]. Different extraction sources also determine the physical properties of HA powder, such as particle size and morphology [2]. Together with the chemical content, the physical properties of HA induce different molecular responses in osteoblasts, which also affect the in vivo performance of HA-based implants [11,28]. For instance, a smaller grain size of HA (nanomaterial) has been associated with better bone matrix synthesis than a larger grain size [46]. Thus, it is important to determine the synthesis method or the natural source and extraction method to obtain HA.

Another important thing that determines the in vivo performance of HA is the grain size. Studies showed that HA fabricated in the nanoscale (<200 nm, nanoHA) enhanced its osteoinductive and osteoconductive properties. The nanoHA was formed using various methods, generally using the hydrothermal treatment method [5,26,27]. HA is a biomaterial that is widely used for bone tissue of different sizes and topographic characteristics. Microscale-sized HA (microHA) is the classical HA used as bone tissue scaffold. The administration of microHA was able to induce new bone growth in the defect area in vivo [9,47]. However, Chandran et al. (2016) showed that the administration of microHA in osteoporotic rats did not provide a higher regeneration efficiency than the sham group [48]. This is also in line with clinical findings [49–51]. RCT by Schlagenhauf et al. (2019) showed that daily use of microHA dentifrice on caries progression was not significantly different from 1400 ppm fluoride toothpaste [49]. In addition, HA dentifrice also did not significantly affect plaque formation rate in chronic periodontitis patients compared to fluoridated control. [51]. This then led to comparison studies of nanoHA and microHA. Studies have proven that nanoHA had superior results compared to microHA in vitro [52–54]. The superior effect of nanoHA was also proven in in vivo studies [55,56]. One of those is the study conducted by Daugela et al. (2018). The authors reported that nanoHA-based bone scaffold provided higher new bone growth than the microHA in a rabbit calvarial defect model [56]. This proves that despite having the same chemical components, nanoHA has a specific mechanism that makes it superior to microHA. It can be emphasized that nanoHA has the ability to bind to target protein on the cell surface, thereby triggering signaling pathway activities that have an impact on new bone growth.

Nanomaterials have a larger surface area than microscale materials. A large surface area increases the wettability of the material. This was proven by the lower contact angle of nanoHA compared to microHA [46]. nanoHA beneficially contributes to the use of this material in biological systems. Bezerra et al. reported that the wettability of nanoHA increased the adsorption of proteins present in the extracellular matrix of bone tissue [57], for instance, fibronectin [58]. Fibronectin biomaterials interact with bone cells by binding

to the integrins present in the cells through the Arg-Gly-Asp (RGD) sequence [58]. This accelerated the differentiation and proliferation of osteoblasts [59,60]. In addition, nanoHA also mimics the size of natural HA found in bone tissue. The formation of HA crystals in bone is still not clearly understood. However, several studies have shown that HA crystal formation begins when osteoblasts deposit crystals to the bone tissue, with a size of approximately 50–200 nm [61,62]. Therefore, nanoHA as biomaterial strongly supports its osteoinductive and osteoconductive properties.

3. Osteoblasts, Their Transcription Factors, and Other Marker Proteins

3.1. *Runx2*

The application of HA as a biomaterial for bone regeneration depends on bone mineralizing cells termed osteoblasts. HA induces the activity of osteoblasts, which increases the synthesis of new bone matrix in bone defects [11]. For this purpose, osteoblasts must be differentiated from their precursor cells, termed multipotential stem cells (MSCs) from marrow [12]. *Runx2* is a master transcription factor expressed on osteoblast lineage cells and chondrocytes. Osteoblast precursor cells which express *Runx2* are referred to as “pre-osteoblasts” [63]. *Runx2*, also termed core binding factor $\alpha 1$ (*Cbfa*), plays a role in almost all phases of osteoblast differentiation [14]. In the absence of osteoblasts, the skeletal system of *Runx2*^{-/-} mice showed a lack of intramembranous or endochondral ossification [64,65]. Of note, *Runx2*^{+/-} mice exhibited skeletal abnormalities [39]. *Runx2* also inhibited the differentiation of chondrocytes from mesenchymal cells during embryogenesis [66]. The expression of *Runx2* decreased over time during the process of osteoblast differentiation [67]. However, overexpression of *Runx2* in the late stage of osteoblast differentiation inhibited osteoblast maturation, decreased bone mass, and caused osteopenia and bone fracture [68]. Thus, it is suggested that *Runx2* negatively regulates the differentiation of osteocytes from osteoblasts. *Runx2* is one of the most common markers investigated in osteoblastic differentiation studies, particularly for early-stage differentiation. It has been shown that biomaterials, such as HA, induce the differentiation of osteoblasts by upregulating *Runx2* [4,26,27].

3.2. *Osterix (Osx)*

Sp7, also termed *Osx*, is one of the transcription factors involved in the early stages of osteoblast differentiation. *Osx*^{-/-} mice continued to express *Runx2*, indicating that *Osx* is a downstream factor of *Runx2*. *Osx*^{-/-} mice failed to form bone, while their preosteoblasts expressed more chondrocyte markers [69]. This suggests that *Osx* is essential in preventing chondrocyte differentiation. Overexpression of *Osx* inhibited the late stage of osteoblast differentiation [13]. *Osx* is also important in bone homeostasis. Inactivation of *Osx* affects the expression of AT-rich sequence-binding protein 2 (*Satb2*) gene, which also a transcription factor that regulates the differentiation of osteoblasts. The *Satb2* gene was downregulated in *Osx*-null calvaria by activating the promoter region of the *Satb2* gene in the GC-rich binding site [70]. Inactivation of *Osx* in the postnatal period caused defects in osteoblast function, followed by decreased bone formation [71]. Together with *Runx2*, *Osx* regulated the unique cartilage matrix-associated protein (*Ucma*) gene. Overexpression of *Ucma* resulted in accelerated mineralized nodule formation [72]. The expression of *Ucma* was decreased in *Runx2/Osx* double heterozygous embryos, while overexpression of *Runx2* and *Osx* increased the activity of the *Ucma* promoter [72]. In line with *Runx2*, HA also induced the expression of *Osx*, which caused osteoblastic differentiation of osteoblast progenitor cells [73]. Thus, *Osx* is also commonly used as a marker for biomaterials-induced osteoblastic differentiation, including HA.

3.3. *ATF4*

ATF4 is a leucine-zipper transcription factor belonging to the ATF/CREB protein family. The *ATF4* gene is expressed during embryonic development and life. In most cells, the *ATF4* protein is degraded through ubiquitination. However, this protein was not degraded

in osteoblasts [15]. ATF4 plays role in bone homeostasis and osteoblastic differentiation from MSCs. Ablation of the ATF4 gene inhibited osteoblast differentiation and reduced β -catenin levels, whereas ATF4 overexpression increased β -catenin in vitro [74]. It has been shown that ATF4 and Runx2 regulate the expression of the osteocalcin (OCN) gene in osteoblasts [75]. Of note, ATF4 induced the expression of OCN in both osteoblasts and non-osteoblastic cells [76]. However, ATF4 is not a common marker investigated in studies related to osteoblastic differentiation.

3.4. *Dlx5*

Dlx5 is a transcription factor that plays important roles in osteoblast and osteoclast activity. It is widely expressed in developing cartilage and in less mature osteoblasts along with Dlx2 and Dlx6; notably, Dlx3 is expressed in mature osteoblasts and osteocytes [77,78]. The femur of embryonic *Dlx5*-null mice exhibited a decrease in both total and trabecular bone volume. In osteoblast cell culture, *Dlx5*^{-/-} decreased osteoblast differentiation and proliferation, and downregulated the *Runx2*, *Osx*, *OCN*, and bone sialoprotein 2 (*BSP*) genes. In the femur of *Dlx5*^{-/-} mice, osteoclast activity and the RANKL/osteoprotegerin (RANKL/OPG) ratio were increased [16]. Suppression of 5A signal transducer and activator of transcription (STAT5A) activated Dlx5 and increased osteogenesis in vitro and in vivo [79]. Meanwhile, deletion of STAT5A increased bone mass and bone density, prevented age-related bone loss, and increased bone remodeling in mice [79]. In addition, Dlx5 mediates BMP2-induced *Runx2* expression and osteoblast differentiation by direct binding to the *Runx2* promoter (sequences between -756 and -342 bp) [80]. Along with *Runx2* and *Osx*, biomaterials also induced the expression of *Dlx5*, including HA [81]. These markers determine the stage of osteoblast differentiation induced by the presence of biomaterials.

3.5. *Msx*

Msx1, also termed Hox 7.1, is a transcription factor associated with several tissues during embryonic development, including bone and teeth. *Msx1* is a regulator of the *OCN* promoter [82]. This transcription factor modulates the expression of various genes, including genes related to cholesterol synthesis during osteoblast differentiation from human dental pulp stem cells (DPSCs) [17]. *Msx1*-null mutation did not cause endochondral ossification in the mandibular condyle [83]. Alongside *Msx1*, *Msx2* is also involved in the craniofacial skeleton. *Msx2* negatively regulates the differentiation of adipocytes by blocking peroxisome proliferator activated receptor gamma (PPAR γ) and the CCAAT/enhancer-binding protein (C/EBP) family [16]. In humans, mutations in *Msx2* caused craniosynostosis [84]. The *Msx1* and *Msx2* were upregulated during fracture repair [85]. These genes are also upregulated by several biomaterials, and used as osteoinductive markers in vitro [86,87].

3.6. Alkaline Phosphatase

ALP is an ectoenzyme that hydrolyzes monophosphate esters. In humans there are four types of ALP: tissue-nonspecific, intestinal, placental, and germ-cell-specific. Tissue-nonspecific alkaline phosphatase (TNALP) is expressed in bone, particularly by osteoblasts [88]. Physiologically, TNAP hydrolyzes inorganic pyrophosphate, which is an inhibitor of HA formation during mineralization, and provides inorganic phosphate for HA formation [19,88,89]. *Alpl*^{-/-} osteoblasts expressed osteopontin (OPN), OCN, COL1, *Runx2*, and other osteogenic markers, but do not initiate mineralization in vitro [90]. Meanwhile, *Alpl*^{-/-} mice exhibited bone defects [91]. ALP has been widely used in various studies as an early marker of osteoblastic differentiation [28]. The expression of ALP gene was decreased following the upregulation of late markers, such as OCN [19]. This is in line with evidence obtained from several studies. At the same time point, HA downregulated the expression of ALP gene and upregulated that of OPN, OCN, and COL1 [5,28]. However, other studies have found that ALP expression was positively correlated with that of osteoblast late markers [1,27]. Periodontal ligament stem cells (PDLCS) cultured on nanosized HA (nanoHA) caused a parallel increase in ALP and OCN

genes expression over time [27]. This effect may be attributed to differences in the chemical and physical characteristics of HA.

3.7. COL1

Collagen proteins are the main proteins present on the bone matrix. COL1 is the most abundant type of collagen protein, which accounts for 90% of the ECM [23]. In adult bone, collagen is in a dense parallel layer that alternates in orientation, parallel to and orthogonal to the axis of load, with approximately 2 mm intervals. HA crystals are deposited on this collagen matrix [89]. Collagen protein is vital for the structural integrity and mechanical resistance of bone tissue [92]. COL1 and osteoblasts have feedback regulation. Osteoblasts activate the *Col1a1* gene by binding of Runx2 to the promoter region of COL1 [89,93]. Osteoblasts are also cells that synthesize COL1 [94]. Conversely, COL1 was reported to induce the expression of osteoblastic genes in MSCs [95]. Thus, COL1 is widely used as a bone graft component to induce tissue regeneration in defective bones [92]. Induction of gene expression and protein synthesis of COL1 was found after culturing osteoblasts on several types of materials, including HA. HA (nanosized, HA-coated surface, and HA composite) induces gene expression and collagen protein synthesis in osteoblasts [4,5].

3.8. Osteopontin

OPN is an acidic glycoposphoprotein expressed by osteoclasts, osteoblasts, osteocytes, and some inflammatory cells [24,96]. Along with BSP, OPN is a member of the SIBLING (small integrin-binding ligand, N-linked glycoprotein) protein family [97]. The expression of OPN depends on Runx2, which activates the promoter of the OPN [98]. OPN plays a role in osteoclast activity. However, its physiological function in osteoblasts has not been widely reported [24]. OPN plays a role in forming the sealing zone for the resorption activity of osteoclasts by binding to $\alpha v \beta 3$ [71]. It also plays a role in the migration of osteoclasts through $\alpha v \beta 3$ and CD44 [99]. HA upregulates the expression and synthesis of OPN with various physical characteristics [1,5,28]. Thus, together with COL1, OPN is a widely used marker of osteoblastic differentiation stimulated by biomaterials in osteoblasts.

3.9. Osteocalcin

OCN is a gamma-carboxyglutamate protein expressed by osteoblasts. It is the most abundant noncollagenous protein in bone tissue that binds calcium ions to the bone [20]. Studies reported that absence of OCN in mice results in greater bone mass. This is because the absence of OCN increased bone formation without disturbing the resorption activity [100]. Therefore, OCN level in osteoblasts is a marker of mineral deposition [20]. OCN is also involved in endocrine regulation, such as insulin production and sugar homeostasis [101]. Biomaterials, such as HA, induce osteoblast differentiation which is characterized by an increase in OCN [1,5,26,27]. However, the physiological function of OCN in osteoblasts and bone matrix synthesis remains unclear and warrants further investigation.

3.10. Osteonectin (ON)

ON, also termed SPARC (secreted protein acidic and rich in cysteine) and BM40, is a protein that binds to calcium. This protein is expressed in mineralized and non-mineralized tissue [22]. *Sparc*-null mice exhibited low bone formation and a low number of both osteoblasts and osteoclasts, leading to decreased bone remodeling and osteopenia [102]. Although ON was detected in non-mineralized tissues, high expression of ON encoding gene was found in the odontoblasts of developing teeth [103]. ON mutant cells exhibited decreased formation of mineralized nodules and a tendency to differentiate into adipocytes, characterized by an increase in adipogenic markers in vitro [104]. ON is also important in procollagen processing, collagen deposition, and its assembly into the ECM [22]. Similar to other non-collagen proteins, ON is commonly used as a marker in the late stage of osteoblastic differentiation. Moreover, it has been reported that its gene expression is induced by materials such as HA [105].

3.11. Osteoprotegerin

OPG is a protein expressed in numerous tissues, especially bone tissue. Previously it was thought that OPG is secreted by B lymphocytes and osteocytes [106,107]. However, deletion of *Tnfrsf11b* (the *OPN* encoding gene) in both cells did not cause significant changes in bone mass. However, deletion of the same gene in osteoblasts increased bone resorption and reduced bone mass in mice [25]. OPG and its ligand RANKL are members of the tumor necrosis factor receptor family and essential in bone resorption activity [108]. The OPG/RANKL/RANK system plays a vital role in the pathological process in bone tissue. The interaction of RANKL and RANK initiates a signaling pathway that activates nuclear factor- κ B (NF- κ B) and regulates gene expression. In contrast, OPG secretion inhibited the resorption activity of bone osteoclasts by binding to RANKL [108]. Expression of the *Tnfrsf11b* gene increases in cultured osteoblasts after the onset of mineralization [109]. OPG also plays a role in maintaining cartilage integrity. *Tnfrsf11b*^{-/-} mice exhibited progressive loss of cartilage matrix and articular cartilage, indicating severe degenerative joint disease [110]. Expression of the *Tnfrsf11b* is induced by various stimuli, including HA as a biomaterial for bone tissue. Prahasanti et al. reported that use of a scaffold containing HA and stem cells increased the expression of OPG and RANKL in vivo [111].

3.12. Bone Sialoprotein 2

BSP is an acidic phosphoprotein that belongs to the SIBLING (Small Integrin-Binding LIgand N-linked Glycoprotein) family. It is expressed on mineralized tissue, including bone tissue, by osteoblasts, osteoclasts, and osteocytes [21]. BSP plays a role in initiating the formation of HA crystals through its polycarboxylate sequence [21,112]. Similar to other noncollagenous proteins, BSP is commonly used as a marker of osteoblast differentiation. Use of biomaterials such as HA increased the expression of the BSP-encoding gene in bone marrow stromal cells (BMSCs) through a specific signaling pathway [26]. Overexpression of the BSP-encoding gene increased osteoblastic differentiation markers, calcium incorporation, and nodule formation in osteoblasts. In contrast, suppression of BSP-encoding gene inhibited the associated markers and nodule formation in vitro [113,114]. In addition, BSP is involved in osteoclast activity. *Ibsp*^{-/-} mice exhibited low bone formation rates that were predicted to occur due to a decrease in resorption activity, marked with lower numbers of osteoclasts [114].

4. HA-Induced Signaling Pathways in Osteoblasts

4.1. Extracellular Signal-Regulated Kinase (ERK) Signaling Pathway

Protein kinases are proteins which catalyze the transfer of a phosphate group from ATP to one or more side chains of a target protein. Protein phosphorylation controls the enzymatic activity of a protein and its interactions with other proteins or molecules [115]. MAPKs are a family of protein kinases that control a series of cellular events ranging from proliferation to controlled cell death [115]. ERK1 and ERK2 are MAPKs involved in cell differentiation. Signaling pathways involving ERK occur due to the induction of growth factors, cytokines, viruses, small compounds, and others, as well as biomaterials (e.g., HA). Ha et al. reported that the administration of nanoHA increased the expression of OPN and decreased that of ALP in BMSCs and the preosteoblast cell line MC3T3-E1; these effects were mediated by the ERK signaling pathway, but not p38 and JNK [28]. In this event, the highest ERK phosphorylation occurred 1 h following exposure to nanoHA [28]; this was similar to the effect induced by the presence of HA [116]. This event occurred due to the interaction of nanoHA (rod-like shape, 10 nm in width, 100 nm in length) with the fibroblast growth factor receptor (Fgfr) and phosphate transporter (PiT). Blockade of these two membrane proteins caused complete inhibition of changes in gene expression [28].

The activation of the ERK pathway is induced by HA as a single material, as well as HA-coated scaffolds. Jang et al. reported that a nanoHA-coated silk scaffold increased the expression of COL3, fibronectin, OCN, ON, OPG, OPN, ALP, and BMP2 genes on DPSCs.

Changes in gene expression occurred due to an increase in ERK activity, particularly after culturing cells with 0.15 g of HA-coated scaffold [105].

The physical characteristics of HA also affected the ERK signaling pathway. Based on the study conducted by Xu et al. micro/nano flake-like HA was the best hierarchical structure in increasing gene expression and osteogenic protein production in MSCs compared with needle-like and rod-like HA. This regulation is mediated by the ERK signaling pathway, but not through p38 or JNK. The cells also exhibited the highest fibronectin adsorption when cultured with micro or nano flake-like HA. This finding suggests that fibronectin may play an essential role in cell and HA interactions, which subsequently induce the ERK signaling pathway [117]. Surface topography also influences cellular regulation of osteoblast due to HA. Xia et al. reported that BMSCs cultured on HA with micro-nano-hybrid surface increased the expression of Runx2, BMP2, BSP, and OCN genes via ERK signaling pathway. Moreover, administration of HA increased cell adhesion, cell viability, and ALP activity. HA with these characteristics provided the best in vivo performance compared to the other types (nanosheet, nanorod, and flat and dense surfaces) [26].

Studies also reported that cell adhesion to materials is influenced by heat energy, which acts as physical stimulation to cells. A three-dimensional-like proliferation pattern was observed in a fibroblast cell line cultured with HA after heat treatment (44 °C for 5 min). This effect was thought to be mediated by p38 activation and involved in cell adhesion to HA [118].

ERK phosphorylation due to HA does not occur exclusively in osteoblasts. Culture of primary human aortic smooth muscle cells with nanoHA increased the expression of Runx2, Osx, and COL1 genes via the ERK signaling pathway. This was confirmed by the administration of an ERK inhibitor prior to cell treatment. This effect may underlie the process of vascular calcification in chronic kidney disease [119].

4.2. p38 Signaling Pathway

p38 is a kinase that conveys signals from cytokines and the immune system. This kinase also plays a role in stress response, cell growth and survival, and differentiation of various cell types [115,120]. Moreover, p38 is essential in osteoblast differentiation. Inhibition of p38 signaling on primary calvarial osteoblasts inhibited ALP activity and mineral deposition. In addition, p38 mediates ECM mineralization regulated by ON [121]. Apart from a role in physiological events in osteoblasts, p38 also plays an important role in osteoblast regulation by HA. Use of a nanoHA-coated silk scaffold (0.03, 0.15, and 0.3 nanoHA) increased the expression of osteogenic genes in DPSCs via the p38 signaling pathway. These genes were COL3, fibronectin, OCN, ON, OPG, OPN, ALP, and BMP2 [105]. Similar results were reported in a study conducted by Suto et al. [122]. Use of nanoHA increased the expression of BMP2 via the p38 signaling pathway, but not ERK, in PDLCS. This occurred without changes in the calcium and phosphate concentrations in culture supernatants [122].

In terms of cellular regulation of osteoblasts, p38 exhibited crosstalk with other molecular pathways, including the ERK signaling pathway. These two pathways increased the expression of Runx2, BMP2, BSP, and OCN genes. This was confirmed through pretreatment of cells with p38 and ERK inhibitors [26].

Other nanomaterials, such as nanosized bioactive glass (size: ~20 nm) [123], and gold (Au) nanoparticles (size: 20 nm and 40 nm) [124,125], also activate the ERK and p38 signaling pathways [123–125]. This proved that the MAPK pathway is involved in the cellular regulation of osteoblasts induced by a wide variety of biomaterials.

4.3. Wnt Signaling Pathway

Wnt is a family of proteins that bind to the seven-pass transmembrane frizzled (FZD) receptors. The Wnt signaling pathway is important in cell determination, proliferation, and differentiation. This signaling is separated into canonical and non-canonical, with the former being the most well studied. This signaling is also termed Wnt/ β -catenin signaling due to its dependence on β -catenin. The Wnt/ β -catenin signaling is activated

by binding to the FZD receptor and coreceptor low-density lipoprotein receptor-related protein 5/6 (LRP5/6). This prevents the phosphorylation and degradation of β -catenin, translating β -catenin into the nucleus and determining the fate of MSC differentiation [114]. Physiologically, Wnt/ β -catenin signaling plays a crucial role in promoting osteoblast differentiation and maintaining bone mass [126,127]. Among other Wnt ligands, Wnt10b is involved in osteoblast differentiation by inducing the expression of Runx2, Dlx5, and Osx, and suppresses the adipogenic transcription factors C/EBP α and PPAR γ [81].

The involvement of the Wnt signaling pathway in osteogenic differentiation occurs in the presence of HA. Culture of PDLs on HA with a micro-nano-hybrid surface increased the expression of Runx2, ALP, OCN, cementum attachment protein (CAP), cementum protein (CEMP), LRP5, and β -catenin genes via the Wnt signaling pathway. However, this study did not measure the levels of phosphorylated β -catenin [27]; thus, it is not possible to determine whether the signaling occurs is through the canonical or non-canonical pathways. In addition, Chen et al. found that use of a HA-coated surface (thickness: 100 μ m) increased the expression of fibronectin, β 1 integrin, vinculin, and paxillin in MSCs, suggesting that the cells adhered to the biomaterial surface [4]. Moreover, the expression of Runx2, Osx, COL1, and OCN genes, as well as ALP activity, were also increased in MSCs, thereby indicating osteogenic differentiation. Pretreatment of cells with Dickkopf-1 (Dkk1) (Wnt signaling inhibitor) confirmed that this event was mediated by the Wnt signaling pathway, particularly the regulation of Wnt10b, β -catenin, Runx2, and Osx [4].

The activation of the Wnt signaling pathway by HA is also influenced by the shape and size of HA particles. Zhou et al. cultured MSCs with strontium-doped HA-coated surface with a nanorod-patterned characteristic. The cells exhibited better adhesion, attachment, spreading, proliferation, and osteogenic differentiation than those shown by cells cultured with a HA-coated surface with a nanogranule-patterned characteristic. This study showed that the proteins regulated by the Wnt/ β -catenin signaling pathway were ALP, OPN, COL1, and OCN [5].

The osteoinductive property of HA-based scaffolds may be enhanced by combining HA with other materials, such as Au. Liang et al. reported that HA-Au nanocomposites increased the expression of β -catenin, Runx2, OCN, and OPN genes, as well as ALP activity in cultured MSCs compared with HA as a single material. These effects and the promotion rate of cell mineralization were dependent on the Wnt/ β -catenin signaling pathway [1].

4.4. BMP Signaling Pathway

BMP and Wnt signaling are two pathways that simultaneously regulate osteoblast differentiation [128]. BMPs are members of the transforming growth factor- β (TGF- β) superfamily and essential for bone homeostasis. More than 30 BMPs are involved in canonical and non-canonical BMP signaling. Unlike non-canonical BMP signaling, canonical BMP signaling depends on Smad [127]. Various studies have shown that the BMP signaling pathway is involved in osteogenic differentiation. Therefore, BMP2 is widely used as a growth factor for tissue engineering [127,129,130].

The BMP signaling pathway also plays a role in osteogenic differentiation induced by HA, particularly in canonical signals (Figure 1). Studies conducted by Tang et al. [131] and Wang et al. [60] found that MSCs cultured with HA (including nanoHA) showed increased expression of osteogenic genes and genes related to the BMP2/Smad signaling pathway, such as *BMPRI*, *BMP2*, *BMP4*, *Smad1*, *Smad4*, and *Smad5* [60,131]. Furthermore, Nahar-Gohad et al. reported a change in gene expression in vascular smooth muscle cells due to the presence of HA. Vascular smooth muscle cells change phenotypes into osteoblast-like cells. Administration of a BMP2 pathway inhibitor blocked the expression of Smad5 and BMP2 proteins in the cells. However, in this study, the expression of other osteogenic genes was not measured after the treatment of cells with a BMP signaling inhibitor [132].




Figure 1. Potential mechanism of the HA-induced signaling pathway. The HA crystals may act as ligands which activate particular signaling receptors and increase the expression of osteogenic transcription factors, indicating osteogenic differentiation.

5. How Do Bone Cells Produce HA?

Several review articles raised that the physiological HA in the bone tissue is formed by matrix vesicle derived from osteoblast. Specifically, calcium and inorganic phosphate ions are transferred by membrane proteins from the extracellular matrix or catalyzed from lipid-driven phospholipids in matrix vesicles [19,133]. However, there is no clear information regarding the molecular mechanism of this event, such as how calcium and inorganic phosphate ions convert to HA in the vesicle matrix, which is still unclear. It is known that HA produced by bone tissue is rod-like nanoHA that forms clusters [61,62,134]. Some studies that investigate the molecular mechanism of extracellular HA also use HA with these characteristics. The studies found that this rod-like nanoHA activated a particular signaling pathway as previously described (Table 1) [5,28]. Thus, it is indicated that bone HA may also activate a particular signaling pathway in bone cells, particularly osteoblast.

Table 1. Signaling pathways induced by hydroxyapatite (HA).

Signaling Pathway	Upregulated Proteins/Genes	HA Characteristics	Technique	References
ERK	ALP	Micro/nano flake-like HA	qRT-PCR, Western blot	[117]
	BMP-2	Micro-nano-hybrid surface	Pharmacologic inhibitors, Western blot	[26]
	BSP	Micro-nano-hybrid surface	Pharmacologic inhibitors, Western blot	[26]
	OCN	Micro-nano-hybrid surface, micro/nano flake-like HA	Pharmacologic inhibitors, qRT-PCR, Western blot	[26,117]
	OPN	Rod-like shaped (10 nm in width and 100 nm in length)	Pharmacologic inhibitors, Western blot	[28]
	Osx	Nanosized HA (<200 nm)	Pharmacologic inhibitors, Western blot	[119]
	Runx2	Micro-nano-hybrid surface, nanosized HA (<200 nm), micro/nano flake-like HA	Pharmacologic inhibitors, qRT-PCR, Western blot	[26,117,119]
	COL1	Nanosized HA (<200 nm), micro/nano flake-like HA	Pharmacologic inhibitors, qRT-PCR, Western blot	[117,119]
p38	BMP-2	Micro-nano-hybrid surface, nanosized HA (<200 nm)	Pharmacologic inhibitors, Western blot	[26,122]
	BSP	Micro-nano-hybrid surface	Pharmacologic inhibitors, Western blot	[26]
	OCN	Micro-nano-hybrid surface, nanosized HA (<200 nm)	Pharmacologic inhibitors, Western blot	[26,119]
	Runx2	Micro-nano-hybrid surface	Pharmacologic inhibitors, Western blot	[26]

Table 1. Cont.

Signaling Pathway	Upregulated Proteins/Genes	HA Characteristics	Technique	References
Wnt	ALP	Micro-nano-hybrid surface, nanorod-patterned strontium-doped HA-coated surface (Sr ₁ -HA), HA-Au nanocomposites	Pharmacologic inhibitors, Western blot	[1,5,27]
	CAP	Micro-nano-hybrid surface	Pharmacologic inhibitors	[27]
	CEMP	Micro-nano-hybrid surface	Pharmacologic inhibitors	[27]
	LRP5	Micro-nano-hybrid surface	Pharmacologic inhibitors	[27]
	OCN	Micro-nano-hybrid surface, nanorod-patterned strontium-doped HA-coated surface (Sr ₁ -HA), HA-Au nanocomposites	Pharmacologic inhibitors, Western blot	[1,5,27]
	OPN	Nanorod-patterned strontium-doped HA-coated surface (Sr ₁ -HA), HA-Au nanocomposites	Pharmacologic inhibitors, Western blot	[1,5]
	Osx	HA-coated surface (100 µm in thickness)	Pharmacologic inhibitors, Western blot	[4]
	Runx2	Micro-nano-hybrid surface, HA-coated surface (100 µm in thickness), HA-Au nanocomposites	Pharmacologic inhibitors, Western blot	[1,4,27]
	COL1	Nanorod-patterned strontium-doped HA-coated surface (Sr ₁ -HA)	Pharmacologic inhibitors, Western blot	[5]
	Wnt10b	HA-coated surface (100 µm in thickness)	Pharmacologic inhibitors, Western blot	[4]
	β-catenin	Micro-nano-hybrid surface, HA-coated surface (100 µm in thickness), HA-Au nanocomposites	Pharmacologic inhibitors, Western blot	[1,4,27]
BMP	ALP	NanoHA-coated surface	qRT-PCR	[60]
	BMP-2	NanoHA-coated surface, HA	qRT-PCR, pharmacologic inhibitors	[60,131,132]
	BMP-4	NanoHA-coated surface, HA	qRT-PCR	[60,131]
	BMPRI	NanoHA-coated surface	qRT-PCR	[60]
	BSP	NanoHA-coated surface, HA	qRT-PCR	[60,131]
	Dlx5	HA	qRT-PCR	[131]
	OCN	HA	qRT-PCR	[131]
	OPN	NanoHA-coated surface, HA	qRT-PCR	[60,131]
	Osx	NanoHA-coated surface, HA	qRT-PCR	[60,131]
	Runx2	NanoHA-coated surface, HA	qRT-PCR	[60,131]
	Smad1	HA	qRT-PCR	[131]
	Smad4	HA	qRT-PCR	[131]
	Smad5	HA	qRT-PCR, pharmacologic inhibitors	[131,132]
	COL1	HA	qRT-PCR	[131]

Notes: Abbreviations: ALP, alkaline phosphatase; BMP, bone morphogenetic protein; BMPRI, bone morphogenetic protein receptor type I; BSP, bone sialoprotein; CAP, cementum attachment protein; CEMP, cementum protein; COL1, type I collagen; Dlx5, distal-less homeobox 5; ERK, extracellular signal-regulated kinase; HA-Au, hydroxyapatite-gold; LRP5, low-density lipoprotein receptor-related protein 5; OCN, osteocalcin; OPN, osteopontin; Osx, osterix; Runx2, Runt-related transcription factor 2; qRT-PCR, quantitative reverse-transcription polymerase chain reaction; Sr₁-HA, nanorod-patterned strontium-doped HA-coated surface.

The current understanding of rod-like nanoHA molecular mechanisms might help understand the mineralization process on bone tissue. In addition, this also helps in understanding the pathological mechanisms in the bone tissue or other tissue that were also predicted to be caused by mineralization [132,135]. This hypothesis can be the potential candidate to move forward in further study.

6. Other Cellular Events Induced by HA

The activation of signaling pathways due to HA not only affected osteoblast differentiation but also adhesion and proliferation. Zhou et al. (2018) reported that the Wnt/β-catenin pathway was the signaling that mediated the adhesion and proliferation of MSCs induced by HA-coated materials [5]. In addition, Mahato et al. reported that the

proliferation of HA-coated glass on osteoblast-like cells was significantly higher than that of non-coated glass [59]. Thus, it is suggested that the increase in cell proliferation rate was due to the presence of HA as intact material.

Furthermore, the particle size of HA also influenced cell proliferation. MSCs cultured on smaller HA exhibited a higher proliferation rate compared to those on larger HA [54]. Not limited to cell proliferation, HA also affected cell adhesion. Xia et al. (2013) reported that HA with nano-structure surface led to better MSCs adhesion and spreading on the biomaterials [26]. This indicated that the proliferation and adhesion of osteoblasts induced by HA were caused by HA as intact material, especially those made in nanoscale.

nanoHA also controversially contributed to cell apoptosis. Remya et al. (2014) demonstrated that nanoHA was not toxic to osteoblasts [136]. However, another study stated that nanoHA inhibited the growth of rat osteoblasts in a dose-dependent manner. nanoHA also significantly induced apoptosis in osteoblasts, with smaller specific surface areas induced lower apoptosis rates [137]. This difference may be due to other topographical cues of HA, such as particle shape. Other than that, this may also be due to the specific signaling pathway that was activated. Therefore, further study of other topographical cues to the activation of signaling pathway is needed.

As reported in the study HA et al. (2015), nanoHA-induced cellular regulation in osteoblast did not occur in cells cultured with nanosized silica [138]. This is also in line with *in vivo* findings; after 15 days of implantation, nanoHA was superior to nano-bioglass, causing the highest bone formation rate [139]. Thus, we indicated that the cellular response induced by nanoHA was due to the material property of nanoHA.

7. Event on the Cell Membrane: Direct Interaction as Intact Ligand or through Ions Release?

As shown in Table 1, HA-induced osteogenic differentiation in the osteoblast cell lineage is mediated by MAPK (particularly ERK and p38 kinases), Wnt, and BMP/ β -catenin signaling pathways. However, the mechanism through which HA stimulates the pathway and the events that occur in the cell membrane remain controversial.

As a biomaterial, HA is generally fabricated in nanosizes to resemble the HA found in humans (i.e., approximately 45 nm in length and 25 nm in width) [28,140]. In general, HA that induces cellular changes in the osteoblast lineage is nanosized [26,28,105,123]. Materials with a size ≤ 100 nm are classified as nanomaterials [141]. Osteogenic differentiation occurs at different rates in cells cultured with materials of different particle sizes. HA with a particle size of 40 nm accelerated the expression of osteoblast-like cell osteogenic genes versus HA with a particle size of 0.5–1.0 μ m [52]. This is in line with the effects induced by HA with a particle size of ~50 and ~100 nm [53]. In addition, the proliferation rate and ALP activity of MSCs cultured with smaller-sized HA (10–100 nm) were higher than those observed in MSCs cultured with larger-sized HA [54]. This is also consistent with *in vivo* findings. Freeze-dried bone allografts with smaller particle sizes caused greater new bone formation in Rhesus monkeys with bone defects [55].

The cellular events induced by HA may be mediated by several possible interactions of HA with the cell membrane. For example, HA may release calcium and phosphate from its crystals. Germaini et al. reported that, after 24 h, nanoHA decreased the concentration of calcium in the culture supernatant of a preosteoblast cell line from 1.3 mM to 0.6 mM [10]. It has been reported that high concentrations of calcium affect the resorption activity of osteoclasts [10]. Jung et al. also reported that calcium released by HA is mediated by the calcium/calmodulin-dependent protein kinase via the L-type calcium channel, which subsequently increases the expression of OPN and BSP genes [142]. This theory is supported by the fact that calcium activates MAPK, which plays a role in cell differentiation [143]. However, Ha et al. reported that the calcium channel did not mediate the changes in HA-induced osteogenic gene expression. The study found that the osteoinductive properties of HA were regulated by Fgfr and PiT, which suggested interacting with HA particles [28]. Furthermore, other studies reported that the concentrations of calcium and phosphate in the culture supernatant of cells treated and not treated with nanoHA were not significantly

different [122]. This suggests that the cellular regulation that occurs in osteoblasts may be due to the function of intact HA.

Endocytosis is one of the critical events in the interaction of biomaterials with cells. Studies have suggested that HA may be internalized by a particular cell and subsequently regulate its gene expression. Liang et al. conducted a study using transmission electron microscopy and detected HA-Au nanoparticles in endosomal vesicles of MSCs [1]. However, other studies yielded opposite results. Ha et al. found that cellular regulation in osteoblasts is not mediated by endocytosis. This was demonstrated through pretreatment of osteoblasts with several inhibitors of the endocytosis process, such as methyl- β -cyclodextrin, inhibitor of clathrin-mediated endocytosis, and inhibitor of micropinocytosis [28]. This study reported that the ERK signaling pathway was involved in cellular regulation in osteoblasts and mediated by the direct interaction of nanosized HA with receptors on osteoblast cells. The administration of Fgfr and PiT caused a full blockade of p-ERK and changes in gene expression. This result was in line with scanning electron microscopy findings; nanoHA was identified on the surface of osteoblasts even after extensive washing, suggesting a strong interaction between material and cells [28]. This suggests that HA, particularly nanosized HA, may act as a ligand for membrane proteins present in osteoblasts, and activates a particular signaling pathway. However, further study is warranted to confirm this hypothesis.

8. Conclusions

Interactions of HA with bone tissue involve a wide variety of cellular events. The physical characteristics of HA influence its osteoinductive properties. NanoHA has been shown to cause cellular changes in osteoblast lineage cells. This type of HA induces osteogenic differentiation via several signaling pathways, including ERK, p38, BMP2, and Wnt signaling pathways. It is suggested that these events are mediated by the interaction of nanoHA particles with receptors present on osteoblasts. NanoHA also provides promising results in terms of in vivo performance. These findings offer new insight into the field of biomaterials and a new strategy for the design of HA to be utilized as a biomaterial for bone tissue engineering. However, further research is required to examine this new design strategy.

Author Contributions: Conceptualization, J.K., M.A.G.; formal analysis, J.K., M.A.G., A.S.B., M.L.A.D.L., E.R., C.A.; writing—original draft preparation, J.K., M.A.G.; visualization, M.A.G.; supervision, J.K., C.A.; project administration, M.A.G., A.S.B., M.L.A.D.L., E.R. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by Ministry of Education and Culture of Republic of Indonesia, through PMDSU research schemes.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data sharing is not applicable to this article.

Acknowledgments: The authors thank Hansen Tandra for help in formatting the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Liang, H.; Xu, X.; Feng, X.; Ma, L.; Deng, X.; Wu, S.; Liu, X.; Yang, C. Gold nanoparticles-loaded hydroxyapatite composites guide osteogenic differentiation of human mesenchymal stem cells through Wnt/ β -catenin signaling pathway. *Int. J. Nanomed.* **2019**, *14*, 6151–6163. [[CrossRef](#)] [[PubMed](#)]
2. Budiati, A.S.; Samirah, N.; Gani, M.A.; Nilamsari, W.P.; Ardianto, C.; Khotib, J. The characterization of bovine bone-derived hydroxyapatite isolated using novel non-hazardous method. *J. Biomim. Biomater. Biomed. Eng.* **2020**, *45*, 49–56. [[CrossRef](#)]
3. Budiati, A.S.; Mahyudin, F.; Khotib, J. Fabrication and characterization of bovine hydroxyapatitegelatin- alendronate scaffold cross-linked by glutaraldehyde for bone regeneration. *J. Basic Clin. Physiol. Pharmacol.* **2021**, in press.

4. Chen, B.; Lin, T.; Yang, X.; Li, Y.; Xie, D.; Zheng, W.; Cui, H.; Deng, W.; Tan, X. Low-magnitude, high-frequency vibration promotes the adhesion and the osteogenic differentiation of bone marrow-derived mesenchymal stem cells cultured on a hydroxyapatite-coated surface: The direct role of Wnt/catenin signaling pathway activation. *Int. J. Mol. Med.* **2016**, *38*, 1531–1540. [[CrossRef](#)] [[PubMed](#)]
5. Zhou, J.; Zhao, L.; Li, B.; Han, Y. Nanorod diameter modulated osteogenic activity of hierarchical micropore/nanorod-patterned coatings via a Wnt/ β -catenin pathway. *Nanomed. Nanotechnol. Biol. Med.* **2018**, *14*, 1719–1731. [[CrossRef](#)]
6. Budiati, A.S.; Zainuddin, M.; Khotib, J. In vitro gentamicin release from bioactive BHAG (ELENA) implant against staphylococcus aureus. *J. Biol. Res.* **2013**, *18*, 116–118. [[CrossRef](#)]
7. Lebre, F.; Sridharan, R.; Sawkins, M.J.; Kelly, D.J.; O'Brien, F.J.; Lavelle, E.C. The shape and size of hydroxyapatite particles dictate inflammatory responses following implantation. *Sci. Rep.* **2017**, *7*, 1–13. [[CrossRef](#)]
8. Liu, W.; Zhang, G.; Wu, J.; Zhang, Y.; Liu, J.; Luo, H.; Shao, L. Insights into the angiogenic effects of nanomaterials: Mechanisms involved and potential applications. *J. Nanobiotechnol.* **2020**, *18*, 1–22. [[CrossRef](#)]
9. Budiati, A.S.; Gani, M.A.; Samirah, N.; Ardianto, C.; Raharjanti, A.M.; Septiani, I.; Putri, N.P.K.P.; Khotib, J. Bovine hydroxyapatite-based bone scaffold with gentamicin accelerates vascularization and remodeling of bone defect. *Int. J. Biomater.* **2021**, *2021*, 1–7. [[CrossRef](#)]
10. Germaini, M.-M.; Detsch, R.; Grünewald, A.; Magnaudeix, A.; Lalloue, F.; Boccaccini, A.R.; Champion, E. Osteoblast and osteoclast responses to A/B type carbonate-substituted hydroxyapatite ceramics for bone regeneration this. *Biomed. Mater.* **2017**, *12*, 035008. [[CrossRef](#)]
11. Khotib, J.; Lasandara, C.S.; Samirah, N.; Budiati, A.S. Acceleration of bone fracture healing through the use of natural bovine hydroxyapatite implant on bone defect animal model. *Folica Med. Indones.* **2019**, *55*, 176–187. [[CrossRef](#)]
12. Raggatt, L.J.; Partridge, N.C. Cellular and molecular mechanisms of bone remodeling. *J. Biol. Chem.* **2010**, *285*, 25103–25108. [[CrossRef](#)]
13. Yoshida, C.A.; Komori, H.; Maruyama, Z.; Miyazaki, T.; Kawasaki, K.; Furuichi, T.; Fukuyama, R.; Mori, M.; Yamana, K.; Nakamura, K.; et al. Sp7 inhibits osteoblast differentiation at a late stage in mice. *PLoS ONE* **2012**, *7*. [[CrossRef](#)]
14. Komori, T. Runx2, an inducer of osteoblast and chondrocyte differentiation. *Histochem. Cell Biol.* **2018**, *149*, 313–323. [[CrossRef](#)] [[PubMed](#)]
15. Zhang, Y.; Lin, T.; Lian, N.; Tao, H.; Li, C.; Li, L.; Yang, X. Hop2 Interacts with ATF4 to promote osteoblast differentiation. *J. Bone Miner. Res.* **2019**, *34*, 2287–2300. [[CrossRef](#)]
16. Samee, N.; Geoffroy, V.; Marty, C.; Schiltz, C.; Vieux-Rochas, M.; Levi, G.; De Vernejoul, M.C. Dlx5, a positive regulator of osteoblastogenesis, is essential for osteoblast-osteoclast coupling. *Am. J. Pathol.* **2008**, *173*, 773–780. [[CrossRef](#)] [[PubMed](#)]
17. Goto, N.; Fujimoto, K.; Fujii, S.; Ida-Yonemochi, H.; Ohshima, H.; Kawamoto, T.; Noshiro, M.; Shukunami, C.; Kozai, K.; Kato, Y. Role of MSX1 in osteogenic differentiation of human dental pulp stem cells. *Stem Cells Int.* **2016**, *2016*. [[CrossRef](#)] [[PubMed](#)]
18. Ichida, F.; Nishimura, R.; Hata, K.; Matsubara, T.; Ikeda, F.; Hisada, K.; Yatani, H.; Cao, X.; Komori, T.; Yamaguchi, A.; et al. Reciprocal roles of Msx2 in regulation of osteoblast and adipocyte differentiation. *J. Biol. Chem.* **2004**, *279*, 34015–34022. [[CrossRef](#)]
19. Vimalraj, S. Alkaline phosphatase: Structure, expression and its function in bone mineralization. *Gene* **2020**, *754*, 144855. [[CrossRef](#)]
20. Neve, A.; Corrado, A.; Cantatore, F.P. Osteocalcin: Skeletal and extra-skeletal effects. *J. Cell. Physiol.* **2013**, *228*, 1149–1153. [[CrossRef](#)]
21. Kruger, T.E.; Miller, A.H.; Godwin, A.K.; Wang, J. Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers. *Crit. Rev. Oncol. Hematol.* **2014**, *89*, 330–341. [[CrossRef](#)]
22. Rosset, E.M.; Bradshaw, A.D. SPARC/osteonectin in mineralized tissue. *Matrix Biol.* **2016**, *52*, 78–87. [[CrossRef](#)]
23. Licini, C.; Vitale-Brovarone, C.; Mattioli-Belmonte, M. Collagen and non-collagenous proteins molecular crosstalk in the pathophysiology of osteoporosis. *Cytokine Growth Factor Rev.* **2019**, *49*, 59–69. [[CrossRef](#)]
24. Luukkonen, J.; Hilli, M.; Nakamura, M.; Ritamo, I.; Valmu, L.; Kauppinen, K.; Tuukkanen, J.; Lehenkari, P. Osteoclasts secrete osteopontin into resorption lacunae during bone resorption. *Histochem. Cell Biol.* **2019**, *151*, 475–487. [[CrossRef](#)] [[PubMed](#)]
25. Cawley, K.M.; Bustamante-Gomez, N.C.; Guha, A.G.; MacLeod, R.S.; Xiong, J.; Gubrij, I.; Liu, Y.; Mulkey, R.; Palmieri, M.; Thostenson, J.D.; et al. Local production of osteoprotegerin by osteoblasts suppresses bone resorption. *Cell Rep.* **2020**, *32*, 108052. [[CrossRef](#)] [[PubMed](#)]
26. Xia, L.; Lin, K.; Jiang, X.; Xu, Y.; Zhang, M.; Chang, J.; Zhang, Z. Enhanced osteogenesis through nano-structured surface design of macroporous hydroxyapatite bioceramic scaffolds via activation of ERK and p38 MAPK signaling pathways. *J. Mater. Chem. B* **2013**, *1*, 5403–5416. [[CrossRef](#)]
27. Mao, L.; Liu, J.; Zhao, J.; Chang, J.; Xia, L.; Jiang, L.; Wang, X.; Lin, K.; Fang, B. Effect of micro-nano-hybrid structured hydroxyapatite bioceramics on osteogenic and cementogenic differentiation of human periodontal ligament stem cell via Wnt signaling pathway. *Int. J. Nanomed.* **2015**, *10*, 7031–7044. [[CrossRef](#)] [[PubMed](#)]
28. Ha, S.W.; Park, J.; Habib, M.M.; Beck, G.R. Nano-hydroxyapatite stimulation of gene expression requires fgf receptor, phosphate transporter, and Erk1/2 signaling. *ACS Appl. Mater. Interfaces* **2017**, *9*, 39185–39196. [[CrossRef](#)] [[PubMed](#)]
29. Ramesh, N.; Moratti, S.C.; Dias, G.J. Hydroxyapatite-polymer biocomposites for bone regeneration: A review of current trends. *J. Biomed. Mater. Res. Part B Appl. Biomater.* **2017**, *106*, 2046–2057. [[CrossRef](#)]
30. Habraken, W.; Habibovic, P.; Epple, M.; Bohner, M. Calcium phosphates in biomedical applications: Materials for the future? *Mater. Today* **2016**, *19*, 69–87. [[CrossRef](#)]

31. Lin, X.; Patil, S.; Gao, Y.G.; Qian, A. The bone extracellular matrix in bone formation and regeneration. *Front. Pharmacol.* **2020**, *11*, 757. [[CrossRef](#)]
32. Kartikasari, N.; Yuliati, A.; Kriswandini, I.L. Compressive strength and porosity tests on bovine hydroxyapatite-gelatin-chitosan scaffolds. *Dent. J. Maj. Kedokt. Gigi* **2016**, *49*, 153. [[CrossRef](#)]
33. Zhou, M.; Geng, Y.M.; Li, S.Y.; Yang, X.B.; Che, Y.J.; Pathak, J.L.; Wu, G. Nanocrystalline hydroxyapatite-based scaffold adsorbs and gives sustained release of osteoinductive growth factor and facilitates bone regeneration in mice ectopic model. *J. Nanomater.* **2019**, *2019*. [[CrossRef](#)]
34. Anghelescu, V.M.; Neculae, I.; Dincă, O.; Vlădan, C.; Socoliuc, C.; Cioplea, M.; Nichita, L.; Popp, C.; Zurac, S.; Bucur, A. Inflammatory-driven angiogenesis in bone augmentation with bovine hydroxyapatite, B-tricalcium phosphate, and bioglasses: A comparative study. *J. Immunol. Res.* **2018**, *2018*. [[CrossRef](#)] [[PubMed](#)]
35. Okanou, Y.; Ikeuchi, M.; Takemasa, R.; Tani, T.; Matsumoto, T.; Sakamoto, M.; Nakasu, M. Comparison of in vivo bioactivity and compressive strength of a novel superporous hydroxyapatite with beta-tricalcium phosphates. *Arch. Orthop. Trauma Surg.* **2012**, *132*, 1603–1610. [[CrossRef](#)]
36. Lee, H.R.; Kim, H.J.; Ko, J.S.; Choi, Y.S.; Ahn, M.W.; Kim, S.; Do, S.H. Comparative characteristics of porous bioceramics for an osteogenic response in vitro and in vivo. *PLoS ONE* **2013**, *8*, e84272. [[CrossRef](#)]
37. Maenhoudt, W.; Hallaert, G.; Kalala, J.P.; Baert, E.; Dewaele, F.; Bauters, W.; Van Roost, D. Hydroxyapatite cranioplasty: A retrospective evaluation of osteointegration in 17 cases. *Acta Neurochir.* **2018**, *160*, 2117–2124. [[CrossRef](#)] [[PubMed](#)]
38. Kato, E.; Yamada, M.; Sakurai, K. Retrospective clinical outcome of nanopolymorphic crystalline hydroxyapatite-coated and anodic oxidized titanium implants for 10 years. *J. Prosthodont. Res.* **2015**, *59*, 62–70. [[CrossRef](#)] [[PubMed](#)]
39. Pieske, O.; Kaltenhauser, F.; Pichlmaier, L.; Schramm, N.; Trentzsch, H.; Löffler, T.; Greiner, A.; Piltz, S. Clinical benefit of hydroxyapatite-coated pins compared with stainless steel pins in external fixation at the wrist: A randomised prospective study. *Injury* **2010**, *41*, 1031–1036. [[CrossRef](#)]
40. Chitsazi, M.T.; Shirmohammadi, A.; Faramarz, M.; Pourabbas, R.; Rostamzadeh, A.N. A clinical comparison of nano-crystalline hydroxyapatite (Ostim) and autogenous bone graft in the treatment of periodontal intrabony defects. *Med. Oral. Patol. Oral. Cir. Bucal.* **2011**, *16*, 448–453. [[CrossRef](#)]
41. Mohd Pu'ad, N.A.S.; Abdul Haq, R.H.; Mohd Noh, H.; Abdullah, H.Z.; Idris, M.I.; Lee, T.C. Synthesis method of hydroxyapatite: A review. *Mater. Today Proc.* **2020**, *29*, 233–239. [[CrossRef](#)]
42. Dorozhkin, S.V. Calcium orthophosphates as bioceramics: State of the art. *J. Funct. Biomater.* **2010**, *1*, 22–107. [[CrossRef](#)]
43. Hokmabad, V.R.; Davaran, S.; Aghazadeh, M.; Alizadeh, E.; Salehi, R.; Ramazani, A. A Comparison of the Effects of Silica and Hydroxyapatite Nanoparticles on Poly(ϵ -caprolactone)-Poly(ethylene glycol)-Poly(ϵ -caprolactone)/Chitosan Nanofibrous Scaffolds for Bone Tissue Engineering. *Tissue Eng. Regen. Med.* **2018**, *15*, 735–750. [[CrossRef](#)]
44. Mohd Pu'ad, N.A.S.; Koshy, P.; Abdullah, H.Z.; Idris, M.I.; Lee, T.C. Syntheses of hydroxyapatite from natural sources. *Heliyon* **2019**, *5*, e01588. [[CrossRef](#)]
45. Rana, M.; Akhtar, N.; Rahman, S.; Jamil, H.M.; Asaduzzaman, S.M. Extraction of Hydroxyapatite from Bovine and Human Cortical Bone by Thermal Decomposition and Effect of Gamma Radiation: A Comparative Study. *Int. J. Complement. Altern. Med.* **2017**, *8*. [[CrossRef](#)]
46. Chen, F.; Wang, M.; Wang, J.; Chen, X.; Li, X.; Xiao, Y.; Zhang, X. Effects of hydroxyapatite surface nano/micro-structure on osteoclast formation and activity. *J. Mater. Chem. B* **2019**, *7*, 7574–7587. [[CrossRef](#)]
47. Liu, J.; Mao, K.; Liu, Z.; Wang, X.; Cui, F.; Guo, W.; Mao, K.; Yang, S. Injectable Biocomposites for Bone Healing in Rabbit Femoral Condyle Defects. *PLoS ONE* **2013**, *8*. [[CrossRef](#)]
48. Chandran, S.; Suresh Babu, S.; Hari Krishnan, V.S.; Varma, H.K.; John, A. Osteogenic efficacy of strontium hydroxyapatite micro-granules in osteoporotic rat model. *J. Biomater. Appl.* **2016**, *31*, 499–509. [[CrossRef](#)] [[PubMed](#)]
49. Schlagenhauf, U.; Kunzelmann, K.H.; Hannig, C.; May, T.W.; Hösl, H.; Gratza, M.; Viergutz, G.; Nazet, M.; Schamberger, S.; Proff, P. Impact of a non-fluoridated microcrystalline hydroxyapatite dentifrice on enamel caries progression in highly caries-susceptible orthodontic patients: A randomized, controlled 6-month trial. *J. Investig. Clin. Dent.* **2019**, *10*, e12399. [[CrossRef](#)]
50. Paszynska, E.; Pawinska, M.; Gawriolek, M.; Kaminska, I.; Otulakowska-Skrzynska, J.; Marczuk-Kolada, G.; Rzatowski, S.; Sokolowska, K.; Olszewska, A.; Schlagenhauf, U.; et al. Impact of a toothpaste with microcrystalline hydroxyapatite on the occurrence of early childhood caries: A 1-year randomized clinical trial. *Sci. Rep.* **2021**, *11*, 1–15. [[CrossRef](#)]
51. Harks, I.; Jockel-Schneider, Y.; Schlagenhauf, U.; May, T.W.; Gravemeier, M.; Prior, K.; Petersilka, G.; Ehmke, B. Impact of the daily use of a microcrystal hydroxyapatite dentifrice on de novo plaque formation and clinical/microbiological parameters of periodontal health. A randomized trial. *PLoS ONE* **2016**, *11*, e0160142. [[CrossRef](#)]
52. Hatakeyama, W.; Taira, M.; Chosa, N.; Kihara, H.; Ishisaki, A.; Kondo, H. Effects of apatite particle size in two apatite/collagen composites on the osteogenic differentiation profile of osteoblastic cells. *Int. J. Mol. Med.* **2013**, *32*, 1255–1261. [[CrossRef](#)]
53. Yang, X.; Li, Y.; Liu, X.; Zhang, R.; Feng, Q. In vitro uptake of hydroxyapatite nanoparticles and their effect on osteogenic differentiation of human mesenchymal stem cells. *Stem Cells Int.* **2018**, *2018*. [[CrossRef](#)]
54. Weißenböck, M.; Stein, E.; Undt, G.; Ewers, R.; Lauer, G.; Turhani, D. Particle size of hydroxyapatite granules calcified from red algae affects the osteogenic potential of human mesenchymal stem cells in vitro. *Cells Tissues Organs* **2006**, *182*, 79–88. [[CrossRef](#)]
55. Shapoff, C.A.; Bowers, G.M.; Levy, B.; Mellonig, J.T.; Yukna, R.A. The Effect of Particle Size on the Osteogenic Activity of Composite Grafts of Allogeneic Freeze-Dried Bone and Autogenous Marrow. *J. Periodontol.* **1980**, *51*, 625–630. [[CrossRef](#)]

56. Daugela, P.; Pranskunas, M.; Juodzbaly, G.; Liesiene, J.; Baniukaitiene, O.; Afonso, A.; Sousa Gomes, P. Novel cellulose/hydroxyapatite scaffolds for bone tissue regeneration: In vitro and in vivo study. *J. Tissue Eng. Regen. Med.* **2018**, *12*, 1195–1208. [[CrossRef](#)] [[PubMed](#)]
57. Bezerra, F.; Ferreira, M.R.; Fontes, G.N.; da Costa Fernandes, C.J.; Andia, D.C.; Cruz, N.C.; da Silva, R.A.; Zambuzzi, W.F. Nano hydroxyapatite-blasted titanium surface affects pre-osteoblast morphology by modulating critical intracellular pathways. *Biotechnol. Bioeng.* **2017**, *114*, 1888–1898. [[CrossRef](#)]
58. Parisi, L.; Toffoli, A.; Ghezzi, B.; Mozzoni, B.; Lumetti, S.; Macaluso, G.M. A glance on the role of fibronectin in controlling cell response at biomaterial interface. *Jpn. Dent. Sci. Rev.* **2020**, *56*, 50–55. [[CrossRef](#)]
59. Mahato, A.; Sandy, Z.; Bysakh, S.; Hupa, L.; Das, I.; Bhattacharjee, P.; Kundu, B.; De, G.; Nandi, S.K.; Vallittu, P.; et al. Development of nano-porous hydroxyapatite coated e-glass for potential bone-tissue engineering application: An in vitro approach. *Mater. Sci. Eng. C* **2020**, *111*, 110764. [[CrossRef](#)] [[PubMed](#)]
60. Wang, J.; Wang, M.; Chen, F.; Wei, Y.; Chen, X.; Zhou, Y.; Yang, X.; Zhu, X.; Tu, C.; Zhang, X. Nano-hydroxyapatite coating promotes porous calcium phosphate ceramic-induced osteogenesis via BMP/SMAD signaling pathway. *Int. J. Nanomed.* **2019**, *14*, 7987–8000. [[CrossRef](#)] [[PubMed](#)]
61. Wu, L.N.Y.; Genge, B.R.; Dunkelberger, D.G.; LeGeros, R.Z.; Concannon, B.; Wuthier, R.E. Physicochemical characterization of the nucleational core of matrix vesicles. *J. Biol. Chem.* **1997**, *272*, 4404–4411. [[CrossRef](#)] [[PubMed](#)]
62. Anderson, H.C.; Garimella, R.; Taugue, S.E. The role of matrix vesicles in growth plate development and biomineralization. *Bone* **2005**, *10*, 822–837. [[CrossRef](#)] [[PubMed](#)]
63. Rutkovskiy, A.; Stenslökken, K.-O.; Vaage, I.J. Osteoblast Differentiation at a Glance. *Med. Sci. Monit. Basic Res.* **2016**, *22*, 95–106. [[CrossRef](#)]
64. Komori, T.; Yagi, H.; Nomura, S.; Yamaguchi, A.; Sasaki, K.; Deguchi, K.; Shimizu, Y.; Bronson, R.T.; Gao, Y.H.; Inada, M.; et al. Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts. *Cell* **1997**, *89*, 755–764. [[CrossRef](#)]
65. Otto, F.; Thornell, A.P.; Crompton, T.; Denzel, A.; Gilmour, K.C.; Rosewell, I.R.; Stamp, G.W.H.; Beddington, R.S.P.; Mundlos, S.; Olsen, B.R.; et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. *Cell* **1997**, *89*, 765–771. [[CrossRef](#)]
66. Maeno, T.; Moriishi, T.; Yoshida, C.A.; Komori, H.; Kanatani, N.; Izumi, S.-I.; Takaoka, K.; Komori, T. Early onset of Runx2 expression caused craniosynostosis, ectopic bone formation, and limb defects. *Bone* **2011**, *49*, 673–682. [[CrossRef](#)] [[PubMed](#)]
67. Beck, G.R. Inorganic phosphate as a signaling molecule in osteoblast differentiation. *J. Cell. Biochem.* **2003**, *90*, 234–243. [[CrossRef](#)]
68. Liu, W.; Toyosawa, S.; Furuichi, T.; Kanatani, N.; Yoshida, C.; Liu, Y.; Himeno, M.; Narai, S.; Yamaguchi, A.; Komori, T. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. *J. Cell Biol.* **2001**, *155*, 157–166. [[CrossRef](#)] [[PubMed](#)]
69. Nakashima, K.; Zhou, X.; Kunkel, G.; Zhang, Z.; Deng, J.M.; Behringer, R.R.; Crombrughe, B. de The Novel Zinc Finger-Containing Transcription Factor Osterix Is Required for Osteoblast Differentiation and Bone Formation. *Cell* **2002**, *108*, 17–29. [[CrossRef](#)]
70. Tang, W.; Li, Y.; Osimiri, L.; Zhang, C. Osteoblast-specific transcription factor osterix (Osx) is an upstream regulator of Satb2 during bone formation. *J. Biol. Chem.* **2011**, *286*, 32995–33002. [[CrossRef](#)] [[PubMed](#)]
71. Baek, W.Y.; de Crombrughe, B.; Kim, J.E. Postnatally induced inactivation of Osterix in osteoblasts results in the reduction of bone formation and maintenance. *Bone* **2010**, *46*, 920–928. [[CrossRef](#)] [[PubMed](#)]
72. Lee, Y.J.; Park, S.Y.; Lee, S.J.; Boo, Y.C.; Choi, J.Y.; Kim, J.E. Ucm, a direct transcriptional target of Runx2 and Osterix, promotes osteoblast differentiation and nodule formation. *Osteoarthritis Cartilage* **2015**, *23*, 1421–1431. [[CrossRef](#)]
73. Chen, Q.; Shou, P.; Zheng, C.; Jiang, M.; Cao, G.; Yang, Q.; Cao, J.; Xie, N.; Velletri, T.; Zhang, X.; et al. Fate decision of mesenchymal stem cells: Adipocytes or osteoblasts? *Cell Death Differ.* **2016**, *23*, 1128–1139. [[CrossRef](#)]
74. Yu, S.; Zhu, K.; Lai, Y.; Zhao, Z.; Fan, J.; Im, H.J.; Chen, D.; Xiao, G. ATF4 promotes β -catenin expression and osteoblastic differentiation of bone marrow mesenchymal stem cells. *Int. J. Biol. Sci.* **2013**, *9*, 256–266. [[CrossRef](#)] [[PubMed](#)]
75. Xiao, G.; Jiang, D.; Ge, C.; Zhao, Z.; Lai, Y.; Boules, H.; Phimpilai, M.; Yang, X.; Karsenty, G.; Franceschi, R.T. Cooperative interactions between activating transcription factor 4 and Runx2/Cbfa1 stimulate osteoblast-specific osteocalcin gene expression. *J. Biol. Chem.* **2005**, *280*, 30689–30696. [[CrossRef](#)] [[PubMed](#)]
76. Yang, X.; Karsenty, G. ATF4, the osteoblast accumulation of which is determined post-translationally, can induce osteoblast-specific gene expression in non-osteoblastic cells. *J. Biol. Chem.* **2004**, *279*, 47109–47114. [[CrossRef](#)]
77. Zhao, G.Q.; Zhao, S.; Zhou, X.; Eberspaecher, H.; Solursh, M.; de Crombrughe, B. rDlx, a novel distal-less-like homeoprotein is expressed in developing cartilages and discrete neuronal tissue. *Dev. Biol.* **1994**, *164*, 37–51. [[CrossRef](#)]
78. Li, H.; Marijanovic, I.; Kronenberg, M.S.; Erceg, I.; Stover, M.L.; Velonis, D.; Mina, M.; Heinrich, J.G.; Harris, S.E.; Upholt, W.B.; et al. Expression and function of Dlx genes in the osteoblast lineage. *Dev. Biol.* **2008**, *316*, 458–470. [[CrossRef](#)] [[PubMed](#)]
79. Lee, K.M.; Park, K.H.; Hwang, J.S.; Lee, M.; Yoon, D.S.; Ryu, H.A.; Jung, H.S.; Park, K.W.; Kim, J.; Park, S.W.; et al. Inhibition of STAT5A promotes osteogenesis by DLX5 regulation. *Cell Death Dis.* **2018**, *9*. [[CrossRef](#)]
80. Lee, M.H.; Kim, Y.J.; Yoon, W.J.; Kim, J.I.; Kim, B.G.; Hwang, Y.S.; Wozney, J.M.; Chi, X.Z.; Bae, S.C.; Choi, K.Y.; et al. Dlx5 specifically regulates Runx2 type II expression by binding to homeodomain-response elements in the Runx2 distal promoter. *J. Biol. Chem.* **2005**, *280*, 35579–35587. [[CrossRef](#)]

81. Bennett, C.N.; Longo, K.A.; Wright, W.S.; Suva, L.J.; Lane, T.F.; Hankenson, K.D.; MacDougald, O.A. Regulation of osteoblastogenesis and bone mass by Wnt10b. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 3324–3329. [[CrossRef](#)]
82. Towler, A.; Rutledge, S.J.; Rodan, G.A. Regulator of the rat osteocalcin promoter. *Mol. Endocrinol.* **1994**, *8*, 1484–1493.
83. Orestes-Cardoso, S.; Nefussi, J.R.; Lezot, F.; Oboeuf, M.; Pereira, M.; Mesbah, M.; Robert, B.; Berdal, A. Msx1 is a regulator of bone formation during development and postnatal growth: In vivo investigations in a transgenic mouse model. *Connect. Tissue Res.* **2002**, *43*, 153–160. [[CrossRef](#)] [[PubMed](#)]
84. Jabs, E.W.; Müller, U.; Li, X.; Ma, L.; Luo, W.; Haworth, I.S.; Klisak, I.; Sparkes, R.; Warman, M.L.; Mulliken, J.B.; et al. A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis. *Cell* **1993**, *75*, 443–450. [[CrossRef](#)]
85. Gersch, R.P.; Lombardo, F.; McGovern, S.C.; Hadjiargyrou, M. Reactivation of Hox gene expression during bone regeneration. *J. Orthop. Res.* **2005**, *23*, 882–890. [[CrossRef](#)]
86. Burns, J.S.; Rasmussen, P.L.; Larsen, K.H.; Schröder, H.D.; Kassem, M. Parameters in three-dimensional osteospheroids of telomerized human mesenchymal (Stromal) stem cells grown on osteoconductive scaffolds that predict in vivo bone-forming potential. *Tissue Eng. Part A* **2010**, *16*, 2331–2342. [[CrossRef](#)]
87. Bhargav, A.; Min, K.S.; Wen Feng, L.; Fuh, J.Y.H.; Rosa, V. Taguchi's methods to optimize the properties and bioactivity of 3D printed polycaprolactone/mineral trioxide aggregate scaffold: Theoretical predictions and experimental validation. *J. Biomed. Mater. Res. Part B Appl. Biomater.* **2019**, *108*, 629–637. [[CrossRef](#)]
88. Orimo, H. The mechanism of mineralization and the role of alkaline phosphatase in health and disease. *J. Nippon Med. Sch.* **2010**, *77*, 4–12. [[CrossRef](#)] [[PubMed](#)]
89. Blair, H.C.; Larrouture, Q.C.; Li, Y.; Lin, H.; Beer-Stoltz, D.; Liu, L.; Tuan, R.S.; Robinson, L.J.; Schlesinger, P.H.; Nelson, D.J. Osteoblast differentiation and bone matrix formation in vivo and in vitro. *Tissue Eng. Part B Rev.* **2017**, *23*, 268–280. [[CrossRef](#)]
90. Wennberg, C.; Hessle, L.; Lundberg, P.; Mauro, S.; Narisawa, S.; Lerner, U.H.; Millán, J.L. Functional characterization of osteoblasts and osteoclasts from alkaline phosphatase knockout mice. *J. Bone Miner. Res.* **2000**, *15*, 1879–1888. [[CrossRef](#)] [[PubMed](#)]
91. Fedde, K.N.; Blair, L.; Silverstein, J.; Coburn, S.P.; Ryan, L.M.; Weinstein, R.S.; Waymire, K.; Narisawa, S.; Millán, J.L.; Macgregor, G.R.; et al. Alkaline Phosphatase Knock-Out Mice Recapitulate the Metabolic and Skeletal Defects of Infantile Hypophosphatasia. *J. Bone Miner. Res.* **1999**, *14*, 2015–2026. [[CrossRef](#)]
92. Stamov, D.R.; Pompe, T. Structure and function of ECM-inspired composite collagen type I scaffolds. *Soft Matter* **2012**, *8*, 10200–10212. [[CrossRef](#)]
93. Kern, B.; Shen, J.; Starbuck, M.; Karsenty, G. Cbfa1 contributes to the osteoblast-specific expression of type I collagen genes. *J. Biol. Chem.* **2001**, *276*, 7101–7107. [[CrossRef](#)] [[PubMed](#)]
94. Bosetti, M.; Zanardi, L.; Hench, L.; Cannas, M. Type I collagen production by osteoblast-like cells cultured in contact with different bioactive glasses. *J. Biomed. Mater. Res. Part A* **2002**, *64*, 189–195. [[CrossRef](#)]
95. Mizuno, M.; Kuboki, Y. Osteoblast-related gene expression of bone marrow cells during the osteoblastic differentiation induced by type I collagen. *J. Biochem.* **2001**, *129*, 133–138. [[CrossRef](#)]
96. Hunter, G.K. Role of osteopontin in modulation of hydroxyapatite formation. *Calcif. Tissue Int.* **2013**, *93*, 348–354. [[CrossRef](#)]
97. Singh, A.; Gill, G.; Kaur, H.; Amhmed, M.; Jakhu, H. Role of osteopontin in bone remodeling and orthodontic tooth movement: A review. *Prog. Orthod.* **2018**, *19*. [[CrossRef](#)]
98. Inman, C.K.; Shore, P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. *J. Biol. Chem.* **2003**, *278*, 48684–48689. [[CrossRef](#)]
99. Chellaiah, M.A.; Hruska, K.A. The integrin $\alpha\beta3$ and CD44 regulate the actions of osteopontin on osteoclast motility. *Calcif. Tissue Int.* **2003**, *72*, 197–205. [[CrossRef](#)]
100. Ducy, P.; Desbois, C.; Boyce, B.; Pinero, G.; Story, B.; Dunstan, C.; Smith, E.; Bonadio, J.; Goldstein, S.; Gundberg, C.; et al. Increased bone formation in osteocalcin-deficient mice. *Nature* **1996**, *382*, 448–452. [[CrossRef](#)]
101. Moser, S.C.; van der Eerden, B.C.J. Osteocalcin—A versatile bone-derived hormone. *Front. Endocrinol.* **2019**, *10*, 4–9. [[CrossRef](#)]
102. Delany, A.M.; Amling, M.; Priemel, M.; Howe, C.; Baron, R.; Canalis, E. Osteopenia and decreased bone formation in osteonectin-deficient mice. *J. Clin. Investig.* **2000**, *105*, 915–923. [[CrossRef](#)]
103. Mundlos, S.; Schwahn, B.; Reichert, T.; Zabel, B. Distribution of osteonectin mRNA and protein during human embryonic and fetal development. *J. Histochem. Cytochem.* **1992**, *40*, 283–291. [[CrossRef](#)]
104. Delany, A.M.; Kalajzic, I.; Bradshaw, A.D.; Sage, E.H.; Canalis, E. Osteonectin-null mutation compromises osteoblast formation, maturation, and survival. *Endocrinology* **2003**, *144*, 2588–2596. [[CrossRef](#)]
105. Jang, H.J.; Lee, E.C.; Kwon, G.J.; Seo, Y.K. The effect of coated nano-hydroxyapatite concentration on scaffolds for osteogenesis. *J. Biomater. Appl.* **2019**, *34*, 827–839. [[CrossRef](#)]
106. Li, Y.; Toraldo, G.; Li, A.; Yang, X.; Zhang, H.; Qian, W.P.; Weitzmann, M.N. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. *Blood* **2007**, *109*, 3839–3848. [[CrossRef](#)] [[PubMed](#)]
107. Kramer, I.; Halleux, C.; Keller, H.; Pegurri, M.; Gooi, J.H.; Weber, P.B.; Feng, J.Q.; Bonewald, L.F.; Kneissel, M. Osteocyte Wnt/ β -catenin signaling is required for normal bone homeostasis. *Mol. Cell. Biol.* **2010**, *30*, 3071–3085. [[CrossRef](#)]
108. Rochette, L.; Meloux, A.; Rigal, E.; Zeller, M.; Cottin, Y.; Vergely, C. The role of osteoprotegerin and its ligands in vascular function. *Int. J. Mol. Sci.* **2019**, *20*, 705. [[CrossRef](#)]

109. Thomas, G.P.; Baker, S.U.K.; Eisman, J.A.; Gardiner, E.M. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. *J. Endocrinol.* **2001**, *170*, 451–460. [[CrossRef](#)]
110. Bolon, B.; Grisanti, M.; Villasenor, K.; Morony, S.; Feige, U.; Simonet, W.S. Generalized degenerative joint disease in osteoprotegerin (Opg) null mutant mice. *Vet. Pathol.* **2015**, *52*, 873–882. [[CrossRef](#)]
111. Prahasanti, C.; Subrata, L.H.; Saskianti, T.; Suardita, K.; Ernawati, D.S. Combined hydroxyapatite scaffold and stem cell from human exfoliated deciduous teeth modulating alveolar bone regeneration via regulating receptor activator of nuclear factor- κ B and osteoprotegerin system. *Iran. J. Med. Sci.* **2019**, *44*, 415–421. [[CrossRef](#)]
112. Hunter, G.K.; Goldberg, H.A. Modulation of crystal formation by bone phosphoproteins: Role of glutamic acid-rich sequences in the nucleation of hydroxyapatite by bone sialoprotein. *Biochem. J.* **1994**, *302*, 175–179. [[CrossRef](#)]
113. Gordon, J.A.R.; Tye, C.E.; Sampaio, A.V.; Underhill, T.M.; Hunter, G.K.; Goldberg, H.A. Bone sialoprotein expression enhances osteoblast differentiation and matrix mineralization in vitro. *Bone* **2007**, *41*, 462–473. [[CrossRef](#)] [[PubMed](#)]
114. Malaval, L.; Wade-Gu ye, N.M.; Boudiffa, M.; Fei, J.; Zirngibl, R.; Chen, F.; Laroche, N.; Roux, J.P.; Burt-Pichat, B.; Duboeuf, F.; et al. Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. *J. Exp. Med.* **2008**, *205*, 1145–1153. [[CrossRef](#)]
115. Johnson, G.L.; Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. *Science* **2002**, *298*, 1911–1912. [[CrossRef](#)]
116. Song, J.H.; Kim, J.H.; Park, S.; Kang, W.; Kim, H.W.; Kim, H.E.; Jang, J.H. Signaling responses of osteoblast cells to hydroxyapatite: The activation of ERK and SOX9. *J. Bone Miner. Metab.* **2008**, *26*, 138–142. [[CrossRef](#)]
117. Xu, D.; Wan, Y.; Li, Z.; Wang, C.; Zou, Q.; Du, C.; Wang, Y. Tailorable hierarchical structures of biomimetic hydroxyapatite micro/nano particles promoting endocytosis and osteogenic differentiation of stem cells. *Biomater. Sci.* **2020**, *8*, 3286–3300. [[CrossRef](#)]
118. Hiragami, F.; Akiyama, J.; Koike, Y.; Kano, Y. Enhancement of hydroxyapatite-mediated three-dimensional-like proliferation of mouse fibroblasts by heat treatment: Effects of heat shock-induced p38 MAPK pathway. *J. Biomed. Mater. Res. Part A* **2005**, *74*, 705–711. [[CrossRef](#)]
119. Gong, L.; Liu, Y.; Qian, J.; Ni, Z.; Fang, W. Hydroxyapatite nanocrystals stimulate osteogenic differentiation in primary human aortic smooth muscle cells by activation of oxidative stress and the ERK pathway. *Int. J. Clin. Exp. Pathol.* **2017**, *10*, 7726–7733.
120. Hu, Y.; Chan, E.; Wang, S.X.; Li, B. Activation of p38 mitogen-activated protein kinase is required for osteoblast differentiation. *Endocrinology* **2003**, *144*, 2068–2074. [[CrossRef](#)] [[PubMed](#)]
121. Zhu, Y.S.; Gu, Y.; Jiang, C.; Chen, L. Osteonectin regulates the extracellular matrix mineralization of osteoblasts through P38 signaling pathway. *J. Cell. Physiol.* **2019**, *235*, 2220–2231. [[CrossRef](#)]
122. Suto, M.; Nemoto, E.; Kanaya, S.; Suzuki, R.; Tsuchiya, M.; Shimauchi, H. Nanohydroxyapatite increases BMP-2 expression via a p38 MAP kinase dependent pathway in periodontal ligament cells. *Arch. Oral Biol.* **2013**, *58*, 1021–1028. [[CrossRef](#)] [[PubMed](#)]
123. Yi, C.; Liu, D.; Fong, C.-C.; Zhang, J.; Yang, M. Gold nanoparticles promote osteogenic differentiation of mesenchymal stem cells through p38 MAPK pathway. *ACS Nano* **2010**, *4*, 6439–6448. [[CrossRef](#)]
124. Gong, W.; Dong, Y.; Wang, S.; Gao, X.; Chen, X. A novel nano-sized bioactive glass stimulates osteogenesis via the MAPK pathway. *RSC Adv.* **2017**, *7*, 13760–13767. [[CrossRef](#)]
125. Zhang, D.; Liu, D.; Zhang, J.; Fong, C.; Yang, M. Gold nanoparticles stimulate differentiation and mineralization of primary osteoblasts through the ERK/MAPK signaling pathway. *Mater. Sci. Eng. C* **2014**, *42*, 70–77. [[CrossRef](#)] [[PubMed](#)]
126. Baron, R.; Kneissel, M. WNT signaling in bone homeostasis and disease: From human mutations to treatments. *Nat. Med.* **2013**, *19*, 179–192. [[CrossRef](#)]
127. Hu, L.; Yin, C.; Zhao, F.; Ali, A.; Ma, J.; Qian, A. Mesenchymal stem cells: Cell fate decision to osteoblast or adipocyte and application in osteoporosis treatment. *Int. J. Mol. Sci.* **2018**, *19*, 360. [[CrossRef](#)]
128. Zhang, R.; Oyajobi, B.O.; Harris, S.E.; Chen, D.; Tsao, C.; Deng, H.-W.; Zhao, M. Wnt/ β -catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. *Bone* **2013**, *52*, 145–156. [[CrossRef](#)] [[PubMed](#)]
129. Wu, S.C.; Hsu, H.C.; Hsu, S.K.; Chang, Y.C.; Ho, W.F. Synthesis of hydroxyapatite from eggshell powders through ball milling and heat treatment. *J. Asian Ceram. Soc.* **2016**, *4*, 85–90. [[CrossRef](#)]
130. Gani, M.A.; Nurhan, A.D.; Budiati, A.S.; Siswodihardjo, S.; Khotib, J. Predicting the molecular mechanism of glucosamine in accelerating bone defect repair by stimulating osteogenic proteins. *J. Basic Clin. Physiol. Pharmacol.* **2021**, in press.
131. Tang, Z.; Wang, Z.; Qing, F.; Ni, Y.; Fan, Y.; Tan, Y.; Zhang, X. Bone morphogenetic protein Smads signaling in mesenchymal stem cells affected by osteoinductive calcium phosphate ceramics. *J. Biomed. Mater. Res. Part A* **2014**, *103*, 1001–1010. [[CrossRef](#)]
132. Nahar-Gohad, P.; Gohad, N.; Tsai, C.C.; Bordia, R.; Vyavahare, N. Rat Aortic Smooth Muscle Cells Cultured on Hydroxyapatite Differentiate into Osteoblast-Like Cells via BMP-2-SMAD-5 Pathway. *Calcif. Tissue Int.* **2015**, *96*, 359–369. [[CrossRef](#)]
133. Michigami, T. Skeletal mineralization: Mechanisms and diseases. *Ann. Pediatr. Endocrinol. Metab.* **2019**, *24*, 213–219. [[CrossRef](#)]
134. Bunocci, E. The locus of initial calcification in cartilage. *Clin. Orthop. Relat. Res.* **1971**, *78*, 108–139. [[CrossRef](#)]
135. Martin, K.J.; Gonz lez, E.A. Metabolic bone disease in chronic kidney disease. *J. Am. Soc. Nephrol.* **2007**, *18*, 875–885. [[CrossRef](#)]
136. Remya, N.S.; Syama, S.; Gayathri, V.; Varma, H.K.; Mohanan, P.V. An in vitro study on the interaction of hydroxyapatite nanoparticles and bone marrow mesenchymal stem cells for assessing the toxicological behaviour. *Colloids Surf. B Biointerfaces* **2014**, *117*, 389–397. [[CrossRef](#)] [[PubMed](#)]

137. Xu, Z.; Liu, C.; Wei, J.; Sun, J. Effects of four types of hydroxyapatite nanoparticles with different nanocrystal morphologies and sizes on apoptosis in rat osteoblasts. *J. Appl. Toxicol.* **2012**, *32*, 429–435. [[CrossRef](#)] [[PubMed](#)]
138. Ha, S.W.; Jang, H.L.; Nam, K.T.; Beck, G.R. Nano-hydroxyapatite modulates osteoblast lineage commitment by stimulation of DNA methylation and regulation of gene expression. *Biomaterials* **2015**, *65*, 32–42. [[CrossRef](#)] [[PubMed](#)]
139. Nosouhian, S.; Razavi, M.; Jafaripozve, N.; Rismanchian, M. Comparative evaluation of hydroxyapatite and nano-bioglass in two forms of conventional micro- and nano-particles in repairing bone defects (an animal study). *Indian J. Dent. Res.* **2015**, *26*, 366–371.
140. Weiner, S.; Price, P.A. Disaggregation of bone into crystals. *Calcif. Tissue Int.* **1986**, *39*, 365–375. [[CrossRef](#)] [[PubMed](#)]
141. Guisbiers, G.; Mejía-Rosales, S.; Leonard Deepak, F. Nanomaterial properties: Size and shape dependencies. *J. Nanomater.* **2012**, *2012*, 2012–2014. [[CrossRef](#)]
142. Jung, G.Y.; Park, Y.J.; Han, J.S. Effects of HA released calcium ion on osteoblast differentiation. *J. Mater. Sci. Mater. Med.* **2010**, *21*, 1649–1654. [[CrossRef](#)] [[PubMed](#)]
143. Agell, N.; Bachs, O.; Rocamora, N.; Villalonga, P. Modulation of the Ras/Raf/MEK/ERK pathway by Ca²⁺, and calmodulin. *Cell. Signal.* **2002**, *14*, 649–654. [[CrossRef](#)]

also developed by scimago:



SCIMAGO INSTITUTIONS RANKINGS



Scimago Journal & Co Enter Journal Title, ISSN or Publisher Name



Home

Journal Rankings

Country Rankings

Viz Tools

Help

About Us

Pharmaceuticals

COUNTRY

SUBJECT AREA AND CATEGORY

PUBLISHER

H-INDEX

Switzerland

Universities and research institutions in Switzerland

Biochemistry, Genetics and Molecular Biology
Molecular Medicine

Pharmacology, Toxicology and Pharmaceutics
Drug Discovery
Pharmaceutical Science

Multidisciplinary Digital Publishing Institute (MDPI)

69

PUBLICATION TYPE

ISSN

COVERAGE

INFORMATION

Journals

14248247

2009-2021

[Homepage](#)

[How to publish in this journal](#)

Jean-Jacques.VANDE NEYNDE@ex.umons.ac.be

SCOPE

Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the length of a paper. The multidisciplinary journal welcomes manuscripts covering a wide range of aspects involved in drug discovery and development. The following topics are considered: Small molecules as drug candidates: drug discovery, drug design, medicinal chemistry, combinatorial chemistry, SAR, structure-property correlations, molecular modeling, pharmacophore, and bioinformatics; Biomolecules, natural products, phages, and cells as therapeutic tools: peptides, aptamers, glycans, antibodies, extracts, bacteriophages, and stem cells; Biological targets and biomarkers: enzymes, receptors, membranes, genes, ion channels, inhibitors, agonists, antagonists, neurons, binding affinity, biofilms, bacteria, viruses, parasites, and protein-protein interactions; Radiopharmaceutical sciences, radiochemistry, (hybrid-)imaging, and nuclear medicine: radiopharmaceuticals, radiotracers, fluorescent dye labeled tracers, contrast agents, PET/CT, PET/MRI RMI, SPECT/CT, and scintigraphy; Pharmacokinetics and pharmacodynamics: pharmaceutical analyses, drug effects, ADME, animal experimentation, and clinical trials; Pharmaceutical preparations and drug delivery: dosage form design, bioconjugates, prodrugs, formulation, metabolites, nanomaterials, nanomedicines, and drug targeting.

 Join the conversation about this journal

 Quartiles







FIND SIMILAR JOURNALS 

1

2

3






us® data as of April 2022

A **Ahmad Khalaf** 2 months ago

External Cites per Doc Cites per Doc



Excited to join this


% International Collaboration



SCImago Team

your participation! Best Regards, SCImago

Citable documents Non-citable documents



Cited Documents Uncited documents





Elena Corera 4 years ago

SCImago Team

Thanks for your participation!




← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scim
```

SCImago Graphica

Explore, visually communicate and make sense of data with our [new data visualization tool](#).



Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:

Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®

EST MODUS IN REBUS
Horatio (Satire 1.1.106)

[Edit Cookie Consent](#)